

A JOURNEY OF HEALING FROM PAST TO THE FUTURE

SUSTAINABILITY REPORT
2019-2020



ABDIIBRAHIM



CONTENTS

About the Report __ 3

Message from the Chairman __ 4

CEO's Message __ 6

SUSTAINABILITY __ 8

Sustainability Strategy __ 9

Sustainability Committee __ 9

Sustainability Milestones __ 10

Sustainability Agenda __ 11

Prioritization Analysis __ 12

Our Values and Contributions to Sustainable Development Goals __ 13

PROFILE __ 17

Abdi İbrahim in a Nutshell __ 18

Vision and Corporate Values __ 22

2019 and 2020 Developments __ 24

COVID-19 Pandemic Actions __ 27

MANAGEMENT __ 29

Key Performance Indicators (KPI) __ 30

Management Strategy __ 31

Organizational Structure __ 34

Business Ethics Principles __ 35

Internal Audit Practices __ 35

Reputation Management __ 35

Stakeholder Relationship Management __ 36

Corporate Memberships and Supported Initiatives __ 37

Awards and Achievements __ 38

PERFORMANCE __ 42

Key Performance Indicators (KPI) __ 43

Major Financial and Operational Indicators __ 44

Production __ 45

Investments __ 50

Marketing and Sales __ 52

International Markets __ 53

Procurement and Supply Chain __ 55

EMPLOYEES __ 56

Key Performance Indicators (KPI) __ 57

Human Resources Strategy __ 58

Human Resources Practices __ 58

Occupational Health and Safety Practices __ 61

SOCIETY __ 62

Key Performance Indicators (KPI) __ 63

Social Investment Studies __ 64

2019 Projects __ 65

2020 Projects __ 67

Philanthropy __ 70

ENVIRONMENT __ 71

Key Performance Indicators (KPI) __ 72

Environmental Sustainability Strategy __ 73

Environmental Impact Mitigation Studies __ 75

2019 and 2020 Savings __ 76

Impact on Biodiversity __ 77

Water Consumption __ 77

Energy Consumption __ 77

Greenhouse Gas Emission __ 78

MEDICAL __ 80

Key Performance Indicators (KPI) __ 81

Medical __ 82

Clinical Studies __ 84

Product Safety (Pharmacovigilance) __ 84

Licensing and Market Access __ 85

Product Information and Consultation Line __ 85

“From the Past to the Future: The Journey of Healing” Illustrations __ 86

Annex __ 87

Contributions to Sustainable Development Goals __ 93

GRI Content Index __ 97

Information __ 107

About the Report

| GRI |
| 102-45 |
| 102-46 |
| 102-50 |

Dr. M. Oğuzcan Bülbül

Public Affairs and Corporate
Communications Director
oguzcan.bulbul@abdiibrahim.com.tr ↗

Megi Erpardo

Public Affairs Manager
megi.erpardo@abdiibrahim.com.tr ↗

Buket Koral Gönüllü

Corporate Communications Manager
buket.koral@abdiibrahim.com.tr

Esra Koca

Corporate Communications Supervisor
esra.erdinc@abdiibrahim.com.tr ↗



From the day of our foundation as Abdi İbrahim Pharmaceuticals San.Tic. A.Ş., we have been focused on sustainability and go to great lengths to inform the public about our corporate, environmental, social and administrative efforts that we realize both internally and in cooperation with our external stakeholders. Since 2010, we have participated in the United Nations Global Compact (UNGC) and are focused on incorporating the global principles of the Convention, which is the basis for the 17 sustainable development goals prioritized by the UN, into all our business procedures, strategies and operations.

We consider the internationally recognized Global Reporting Initiative (GRI) to be our guide and since 2013 we are sharing our sustainability reports biannually, which are prepared in accordance with the GRI Standards with the public.

5. Our Sustainability Report covers the period from January 1, 2019 to December 31, 2020. We have prepared this report in accordance with the option "GRI Standards: Core Option". Our report also includes progress within the scope of the 11th Communication on Progress by the UNGC, Communication on Progress on Women's Empowerment Principles (WEPs) and UNGC CEO Water Mandate, on top of being the first corporate sustainability report in Turkey to make use of GRI's SDG Mapping Service. This report includes qualitative and quantitative data on the production facilities and field business units in Turkey and Abdi İbrahim headquarters. Moreover, it also contains detailed information on our systematic and comprehensive projects and objectives, which we realize with internal and external stakeholders in light of the significance and stakeholder participation principles

of the reporting requirements of initiatives, to which we are signatory. We should also state that the Scope 1, Scope 2 and Scope 3 Carbon emission values of the environmental performance indicators in our report for the years 2019 and 2020 have been verified by the independent limited assurance study conducted by PwC.

As can be seen in our report, we are proud to have realized major initiatives and firsts regarding sustainability in the years 2019 and 2020. In line with our objective of a carbon neutral Abdi İbrahim by 2030, we have become the first Turkish pharma company to use 100% renewable energy, by meeting the electricity needs of all production facilities in our Esenyurt Production Complex in Istanbul from solar and wind power plants. We have become the first Turkish pharma company to join the signatories of CEO Water Mandate, the United Nations Global Compact initiative on water sustainability. With this signature, we support the water protection policies carried out across the world through our company commitments. In addition, we have become a member of the Carbon Disclosure Project (CDP). In the first report we made as part of the Climate Change and Water Safety Programs, we made it onto the B- list by ranking above the general average at a global level.

Our aim is to maintain this level of implementation and scope in our future reports in which we describe our sustainability efforts in detail. We attach great importance to the opinions of our stakeholders in all procedures. In this context, you may reach out to our Public Relations and Corporate Communications Directorate Team using the contact information on the left for all your contributions, suggestions, questions and feedback.

Message from the Chairman

Our aim is to leave a "good" impression on the world

PHAR. NEZİH BARUT

As Abdi İbrahim, our focus is to implement practices in the area of sustainability and to serve as an inspiration for our sector and the business world, driven by the confidence of having achieved many firsts in the Turkish pharmaceutical industry. We continue our work wholeheartedly, and are taking major steps to contribute towards the goal of leaving a more habitable and environmentally-friendly world for future generations.



Dear Stakeholders,

Abdi İbrahim, which was founded in 1912 as a small pharmacy established by Pharmacist Abdi Nadir İbrahim Bey in the Küçükmustafapaşa district of Istanbul, continues to serve humanity with the same passion for healing and an unending determination. In line with the long term vision of its founders, our company has grown day by day to become a healing force in a changing world, and its aim is to introduce sustainability to its century-long, successful journey.

In our production facilities, which are equipped with advanced technology and thanks to our qualified human resources, we continue to develop our own products and work with almost 30 licensors. With more than 200 brands and over 400 products, we maintain the status of "the company with the largest portfolio in the pharmaceutical industry." While maintaining our leadership in the industry since 2002, with our 4,600 employees we are improving the lives we touch in more than 60 countries, from European Union countries to Canada, from North Africa to Asia.

As a leading company, we are aware of our responsibilities towards achieving a healthier society and a more habitable world. With our corporate citizen identity, sectoral mission, social priorities, universal principles and sensitivities, we act within the framework

of respect for humans, nature and universal values in all our environmental, social and managerial activities. In this direction, we take great care to present our development processes and the results we have achieved to the attention of our stakeholders and the public. We are pleased to present our 5th Sustainability Report, prepared with this sensitivity and covering the period from 1 January 2019 to 31 December 2020, to your attention as our esteemed stakeholders.

The report we have prepared in accordance with the option "GRI Standards: Core Option" of the Global Reporting Initiative and which is recognized for its significance worldwide, also includes the advances made within the scope of The 11th Communication on Progress of the UNGC, Communication on Progress on Women's Empowerment Principles (WEPs) and the UNGC CEO Water Mandate. Our report includes detailed information about our systematic and comprehensive projects that we have realized with our stakeholders in various areas, from the environment to investment and from employment to social responsibility.

For us, sustainability is a fundamental part of our doctrine that is the guarantee of our work and life. We consider this understanding, which we display with courage, passion and responsibility towards each of our stakeholders as well as that of the world

For us, sustainability is a fundamental part of our doctrine that is the guarantee of our work and life. We consider this understanding, which we display with courage, passion and responsibility towards each of our stakeholders as well as that of the world and society in we live, as a long journey that focuses on development and common interests.

and society in we live, as a long journey that focuses on development and common interests. In this context, we have taken very important steps in recent years of which we are justifiably proud. I would like to state that we will continue our environmental, social and managerial projects without interruption, which lead the sector and the business world in the field of sustainability.

Thanks to the rapid actions we have taken in the face of opportunities and threats, and our long term strategic plans, our investments have continued without interruption, despite all the economic fluctuations during 2019 and 2020 when many difficulties were being experienced both in Turkey and around the world. We have created additional employment in Turkey and in international markets. We continued to strengthen our relations with our stakeholders. During this process, our biggest aim has been to not to impede access our people's access to pharmaceuticals. In the process combatting COVID-19, which has led to sudden and drastic changes globally, we put our R&D and production capacity, medical capabilities, as well as all our expertise and experience, at the service of Turkish medicine and patients. We hastily procured from distant markets the raw materials of the drug rated as effective in the treatment of COVID-19 and ensured a rapid production process to donate 1.6 million tablets to our Ministry of Health. We have also donated more than 250,000 tablets to Kazakhstan and Algeria, where our factories are located. Furthermore, in a brief timeframe as short as one week, we have completed the technology transfer of the drug with the active ingredient Favipiravir, which was developed by TOBIO Novelfarma and has been included in the COVID-19 treatment protocol. You can review the details of each of these steps in our Sustainability Report.

Since the day of our foundation, we have been a growth-oriented company that has emerged from crises stronger, and which leads the industry in many areas. We believe in the potential, strength and future of the Turkish pharmaceutical industry, which we helped to establish in the first place, and will continue our investments even in the most difficult times. In this context, in 2020 we had the honor of presenting yet another first to our country. By purchasing OM Pharma, one of the leading biotechnological pharmaceutical companies in Switzerland, together with a Swiss joint venture group, we are the first Turkish company to become a strategic partner with a Western pharma company. We are honored to represent our industry abroad with this partnership, as we work towards our goal of becoming a strong international player.

As a company, we have determined our strategic goals for 2025 within the framework of "courage, passion and responsibility," values that have shaped us for more than a century. In the coming period, we will increase our activity in international markets, while ensuring a level of growth that will reinforce our leadership in Turkey.

As in the past, we will continue to conduct our activities on responsibly protecting the planet we live in, bequeathing a more habitable world to future generations. We will continue to follow the 2030 Sustainable Development Goals and prioritize activities that will support the nine goals we have identified and which are aligned with our strategies.

Kind regards

**PHAR. NEZİH BARUT
CHAIRMAN**

CEO's Message

We continue to pursue great goals and great ideals

DR. SÜHA TAŞPOLATOĞLU

Our wish is to repay our obligation to our homeland through investment, production, exports and employment. We are conveying our "healing" journey, which began in 1912, to the future, as an influential player that is rising rapidly in international markets with the strength we derive from our well-established corporate culture.



Dear Stakeholders,

As a company with an established history of 109 years, we have been holding our title as the industry leader with pride since 2002. And through our determination, daring breakthroughs and our responsibility towards our country, as well as the passion we have for our work, we are striding towards great goals. Our future is tied to that of our country with a 100 percent domestic capital, and we are acting with the belief that each step we take towards growth creates added value for our brand and our country.

With our strong vision and innovation-oriented development approach, we made significant breakthroughs in 2019 and 2020. As you know, the pandemic we faced in 2020 had important reflections on the pharmaceutical industry. The pandemic, which has revealed the strategic importance and value of domestic production, has seen the emergence of "digitalization" including for example, remote promotion, online launches, and remote inspection options that have initiated new business models and new ideas. At Abdi İbrahim, we are working with everything we have at our disposal to stand by our people during this difficult time. As soon as the pandemic began, we have taken every measure at our disposal and focused on ensuring the public's uninterrupted access to pharmaceuticals. In the mean time, we have kept a close track of procedures, by mobilizing

our resources to contribute towards the fight against COVID-19. In addition to giving us the opportunity to see the impact and beneficial results of a job well done, the pandemic has also enabled us to test those points where we need to improve.

In such a difficult time, we have taken significant steps towards increasing our activity in international markets and becoming a more assertive player in biotechnology, by taking over OM Pharma, one of Switzerland's leading biotechnological pharma companies, together with a Swiss venture group. It gives us great satisfaction to have demonstrated our power with a move that resonates globally.

Sustainability is at the heart of every step we take at Abdi İbrahim and we are committed to integrating it to every link of our value chain. Our sustainability efforts are among our strategic priorities with monitoring at the level of the Board of Directors, and are being built using an ESG (Environmental, Social, Governance) perspective. We realize all our business processes with the awareness that the human health is dependent on the well-being of our planet and taking care to minimize our carbon footprint. Our aim is to pioneer sustainability centered on the transformation of the Turkish pharmaceutical industry, starting with lower carbon emissions. We are proud to have realized several major initiatives and firsts regarding this, during the years 2019 and 2020.

In line with our 2025 vision, which will shape our company's future over the next five-years, our aim is to continue our leadership by growing more than the market in Turkey, Abdi İbrahim will become twice as strong with robust and assertive growth in the international arena.

We took one of the most tangible steps of our sustainability-oriented approach on January 1, 2020. As of this date, we have become the first Turkish pharma company to use 100% renewable energy by meeting the electricity needs of all our production facilities at our Esenyurt Production Complex in Istanbul from solar and wind power plants. In the year 2020, our energy consumption in our production complex was 44,209,606 kilowatt hours, an energy consumption equivalent to the yearly electricity consumption of 26,000 houses, met from renewable sources. With this, we have prevented carbon emissions equivalent to a year's use of 5,230 vehicles. Thus, we have been able to reduce our overall carbon footprint by an equivalent of approximately 24,000 tons of CO₂ and our carbon footprint resulting from electricity consumption to zero. Taking all our activities into consideration, we have reduced our total carbon footprint by approximately 53 percent. Our aim is to reduce the carbon footprint of our company to zero by 2030, with the gradual introduction of renewable energy in all our processes.

We have become the first Turkish pharma company to join the signatories of CEO Water Mandate, the United Nations Global Compact initiative on water sustainability. This signature means that we can continue to support water protection policies globally, through our commitments as a company. In addition, we have become a member of the Carbon Disclosure Project (CDP). In the first report we made as part of the Climate Change and Water Safety Programs, we made it onto the B- list by ranking above the general average at a global level.

The efforts we are making towards sustainability will continue unceasingly in the coming period. To achieve our goals in

this field, we are engaged in multifaceted cooperation with the best Turkish companies and start-ups in their areas of specialization, for the use of electrical vehicles and trucks in the logistics department, the reduction of packaging waste and the development of new, more environmentally friendly kinds of packaging. Participating in platforms, such as CDP and SBTi, where our company can share its sustainability initiative as well as benefit from the experience of other members, and obtaining the "B Corp Certificate" for our company, represents another significant goal for us.

As part of our sustainability efforts, we also attach great importance to social investment programs. We consider our long-term and result-oriented work, which are aimed at providing social benefits, as an integral part of our essential duties. We are excited to be launching a new social investment program in 2021, in light of the corporate reputation, perception research studies and social benefit analyses we have carried out.

In line with our 2025 vision, which will shape our company's future over the next five-years, our aim is to continue our leadership by growing more than the market in Turkey, Abdi İbrahim will become twice as strong with robust and assertive growth in the international arena.

We will continue to achieve our goals with courage and passion, while opening doors to a healthier, more viable and better future for those whose lives we touch.


Kind regards

DR. SÜHA TAŞPOLATOĞLU
CEO

SUSTAINABILITY

A long journey focused on development and mutual benefit

Working for a better world and a better future with its corporate citizen identity, sectoral mission and social priorities, Abdi Ibrahim acts within the framework of respect for human, nature and universal values in all its environmental, social and managerial activities.



Sustainability Strategy

Abdi İbrahim, which has invested in its homeland for more than a century with the mission of "healing life", has built its sustainability strategy in 2020 around a discourse characterized as, "we are healing the future."



Dr. M. Oğuzcan Bülbül
Abdi İbrahim
Public Affairs and Corporate
Communications Director

Sustainability Vision

To create sustainable value by improving the lives we touch; to take part in solutions that respond to the changing living habits, trends shaping the future, national and global requirements and stakeholder expectations regarding the fight against climate change, in order to keep up with the rapid changes we are experiencing.

Sustainability Policy

We see sustainability as a fundamental area of learning that is the guarantee of our work and life. For us, this is a long journey centered around improvement and common interest, in which we demonstrate an approach of courage and passion towards all stakeholders, whether they relate to the world, or the society in which we live, or in our business.

Sustainability Steps

We are faced with consequences, due to climate change, one of the major global risks we are facing today. These include an increase in natural disasters, more frequent extreme weather conditions, the melting of glaciers, droughts

and water scarcity, the loss of food resources and increases in infectious diseases. This is why the "green transformation" that has begun all over the world, is an important step for our future. Abdi İbrahim takes responsibility for the future of the world and humanity, and continues its efforts to be a part of this transformation with the steps and endeavors it is taking towards sustainability.

Abdi İbrahim has taken significant steps by showing extraordinary endeavors during the COVID-19 pandemic which has highlighted the importance of green transformation and sustainability; and it continues to make improvements on all of its work procedures for a better future in light of The European Green Deal, the 17 Sustainable Development Goals (SDG) of the UN, and the many sustainability studies it carries out as a company such as prioritization analysis as well as Organizational Life Assessment Analysis (O-LCA). In this context, in addition to the circular economy projects that will reduce the company's carbon footprint, academy-industry collaborations are being undertaken to realize many projects, including pharmaceuticals without package insert, medicine package and the blister optimization process for decreasing the use of material, in particular plastic, and the production of biodegradable or personalized vitamins and pharmaceuticals using 3D printing.

Acting with a passion for healing and a sense of social responsibility since the day it was founded, Abdi İbrahim focuses on integrating sustainability into every link of its value chain. Our actions are shaped around an ESG (Environmental, Social, Governance) standpoint. This way, we have the opportunity to measure our company's performance not only by positive financial results, but also by taking into account the positive effects we have created for society and the environment.

As we lead the pharmaceutical industry in every way, our aim is to open the doors to a healthier, more viable and better future for those people whom we reach. In this context, we take pride in and get satisfaction from making ambitious moves that serve as an inspiration for all companies, within the framework of our sustainability efforts in 2019 and 2020, in the course of which there have been disasters as a result of climate change. In light of this understanding, we will continue to operate at the intersection of economic, social and environmental values, to pursue what is good for society and the environment, and to create difference and value for the world, in a way that can positively impact all stakeholders.

Sustainability Committee

Sustainability efforts, which are among the strategic priorities of Abdi İbrahim, are managed at the highest level, and that is the Board of Directors. The Sustainability Committee, comprising 40 volunteers led by Abdi İbrahim CEO Dr. Süha Taşpolatoğlu, convenes twice a year to evaluate company performance in relation to objectives, and reviews sustainability efforts.

Your feedback is important

Contact the Sustainability Committee to share your views and suggestions about Abdi İbrahim's sustainability efforts and to obtain more detailed information.

Sustainability Committee
surdurulebilirlik@abdiibrahim.com.tr ➔



Sustainability Milestones

Acting with the awareness that human health depends on the well-being of our planet, Abdi İbrahim continues to be part of the solution for a better future and to lead the sector in this regard, by closely following international standards through its membership in globally accepted initiatives within the area of sustainability.

<h2>Sustainability Milestones</h2> <p>Acting with the awareness that human health depends on the well-being of our planet, Abdi İbrahim continues to be part of the solution for a better future and to lead the sector in this regard, by closely following international standards through its membership in globally accepted initiatives within the area of sustainability.</p>			<p>2005 →</p> <p>Started working with the Environmental Protection and Packaging Waste Recovery Foundation (ÇEVKO). Since then, the Green Dot mark has been present on all our product packaging.</p> 	<p>2010 →</p> <p>Signed the UN Global Compact (UNGC).</p> 	<p>2011 →</p> <p>1st Progress Report on UN Global Compact published.</p>  abdiibrahim.com.tr/en/sustainability/reports
<p>2013 →</p> <p>Publication of the 1st Sustainability Report, prepared in line with GRI principles.</p>  abdiibrahim.com.tr/en/sustainability/reports	<p>2015 →</p> <p>Publication of the 2nd Sustainability Report (GRI).</p>  abdiibrahim.com.tr/en/sustainability/reports	<p>2016 →</p> <p>We became the first and only pharma company to win the Green Dot Industry Award in the Green Dot Industry Awards Competition, organized by ÇEVKO.</p> 	<p>2017 →</p> <p>We signed the Women's Empowerment Principles (WEPs), the private sector initiative of the United Nations.</p> <p>WOMEN'S EMPOWERMENT PRINCIPLES</p>	<p>→</p> <p>Publication of the 3rd Sustainability Report (GRI).</p>  abdiibrahim.com.tr/en/sustainability/reports	
<p>2019 →</p> <p>We became a member of the Business World and Sustainable Development Association (SKD Turkey).</p> 	<p>→</p> <p>We became a member of the Carbon Disclosure Project (CDP).</p> 	<p>→</p> <p>Publication of the 4th Sustainability Report (GRI).</p>  abdiibrahim.com.tr/en/sustainability/reports	<p>2020 →</p> <p>We became the first Turkish pharma company to transition to 100 percent renewable energy.</p> 	<p>→</p> <p>We became the first Turkish pharma company to sign the UNGC CEO Water Mandate initiative.</p> 	<p>→</p> <p>We became the first Turkish pharma company to sign the Science-Based Targets Initiative (SBTi).</p> 
<p>→</p> <p>We became the first Turkish company to sign the Recover Better declaration, which was established under the leadership of UN and SBTi.</p> <p>RECOVER BETTER.</p>	<p>→</p> <p>We qualified for the B- list in CDP with a performance above the global average in the Biotechnology & Pharmaceutical sector.</p> 	<p>→</p> <p>We signed the Plastics Initiative in Business (İPG).</p> <p>İpg İŞ DÜNYASI PLASTİK GİRİŞİMİ</p>	<p>→</p> <p>We became a member of the Turkey Circular Economy Platform.</p> 	<p>→</p> <p>We became a member of the Turkey Materials Marketplace (TMM) initiative.</p> <p>Türkiye materials marketplace</p>	<p>→</p> <p>Publication of the 10th Progress Report on UN Global Compact.</p>  abdiibrahim.com.tr/en/sustainability/reports

Sustainability Agenda

Abdi İbrahim pursues an active agenda leading the sector in terms of sustainability and continues its projects on environmental, social and managerial issues. Here are some of the outstanding projects on the agenda:

The implementation of renewable energy use will continue beyond production with the aim of carbon neutrality by 2030.



Investments and projects aimed at water safety and reduced water consumption will continue.



CDP application for 2021 will be made.



Volunteering hours per employee will be tracked as a KPI.



We have initiated studies to reduce environmental impacts in R&D and innovation activities. In this context, studies will be implemented to decrease Abdi İbrahim's carbon footprint, including pharmaceuticals without package inserts, a medicine package and blister optimization process for the decreased use of material and in particular plastic, biodegradable blister implementation and the production of personalized vitamins and pharmaceuticals using 3D printing.



SBTi target setting application will be made.



The Socioeconomic Impact Report studies that have been initiated will continue.



From the "Social Innovation in Health" standpoint, a program yet to be launched will gather creative ideas and support entrepreneurship.



The Abdi İbrahim Foundation, which is currently being established; will operate in the fields of sports, education, health and care services. As its first project, Abdi İbrahim Charity Residences will be established to accommodate children diagnosed with cancer during their treatment, together with their families.



Organizational Life Cycle Analysis (O-LCA) studies will continue. The roadmap defined within the framework of O-LCA will determine the direction of future studies.



A Community Investment Program will be implemented. Within this program, four main areas of focus will be established: "Health and Sports"; "Social Innovation in Health"; "Raising Scientific Awareness in Youth" and "Volunteering Projects for Social Needs."



Efforts will continue to make financial gains made within managerial steps sustainable, as well as achieve perfection in work ethics and transparency, fight against corruption, pharmaceutical safety and side effects, risk and adaptation processes.



A structure to be established within the company (executive board, project coordinators, volunteers) with the motto "those healing life" will work towards addressing social needs (food aid, afforestation, audiobook voicing, visiting the elderly, disaster training, health literacy, nutrition, preventive health, mentoring, child development, personal development, hobbies, experience sharing on career path, runs for fundraising).



As part of the circular economy studies, projects such as package inserts and boxes made of recycled paper, blisters that can be produced with more environmentally friendly alternative polymers and waste pharmaceutical projects will be implemented.



Prioritization Analysis

| GRI |
102-21	102-42	102-43
102-44	102-46	102-47
103-2	205-1	416-1

In line with the company's business strategy, a comprehensive prioritization analysis study was conducted in 2020 to reveal the environmental, social, managerial and economic issues that will create the greatest impact and value for Abdi İbrahim and its stakeholders. A matrix has been prepared from priority issues determined in line with opinions received from internal and external stakeholders across a large sample, and this forms the basis of the company's sustainability strategy.

Prioritized Issues


- Access to pharmaceuticals
- Pricing
- Inclusivity and diversity
- Gender equality
- Human rights
- Data security and privacy
- Water management
- Animal experiments
- Biodiversity

High Priority Issues

- Drug safety and side effects
- Intellectual property patent
- Community investment programs
- Climate change and energy management
- Waste management
- Business ethics and transparency
- Employee satisfaction
- Occupational health and safety
- Corruption and bribery

Very High Priority Issues

- R&D and innovation
- Talent management
- Stakeholder relations
- Biotech products






















Our Values and Contributions to Sustainable Development Goals



Guided by the United Nations' Sustainable Development Goals (SDGs), the universal call for action to eliminate poverty, protect our planet, and ensure peace and welfare for everyone, Abdi Ibrahim has determined its actions on sustainability in line with its priority analysis conducted in 2020.

In light of its three values –courage, passion and responsibility– Abdi Ibrahim has organized these priorities in a way that will work towards nine SDGs concurrently, taking into consideration the 2030 agenda of United Nations and it is driven by the belief that, by using its capabilities, competences and existing resources, it will contribute towards and have a lasting impact on these global objectives at each step.










Our Values		Description	Our Related Prioritization Topics	SDGs We Support
WE ARE ACCOUNTABLE	We are accountable to our shareholders	We use our resources effectively, efficiently and economically, to grow profitably, balance resource allocation between the short and the long term and make new investments that enable the implementation of company long-term strategies, ultimately ensuring sustainable growth in value for our shareholders.	• Stakeholder Relations	   
	We are environmentally accountable	To minimize our impact on the environment we live in and to become part of a solution for a better future, we are working to increase our energy efficiency, reduce our GHG emissions, protect biodiversity, increase our use of electricity from renewable sources, use the least possible amount of water in production processes, reduce our waste water and packaging waste, and use more environmentally friendly packaging materials.	• Climate Change • Energy Management • Waste and Packaging Management • Water Management • Biodiversity	   
	We are accountable to our business partners	<div>We strive to establish and maintain stakeholder relationships that are fair and based on the rule of law, in which care is taken to protect personal data and operate mutual feedback processes on the basis of ethics and transparency principles within the framework of corporate management principles and where all legal regulations are applied.</div> <div>In line with our company's sustainability strategies, we endeavor to select our suppliers, one of the most important aspects of our production process, in a fair and transparent manner, taking into account their compliance with environmental, social and economic sustainability criteria.</div>	• Stakeholder Relations • Data Security and Privacy • Fight Against Corruption and Bribery • Business Ethics and Transparency • Intellectual Property and Patent	 
	We are accountable to society	In order to be a company that creates value for its stakeholders in a sustainable way, we work towards addressing the needs of society through social benefit projects, in-company volunteering activities and partnerships with non-governmental organizations, social innovations and donations.	• Community Investment Programs • Stakeholder Relations	

Our Values		Description	Our Related Prioritization Topics	SDGs We Support
WE ARE COURAGEOUS	We heal the lives of our patients	By taking advantage of industry 4.0, we continue investing in R&D, digitalization, artificial intelligence and innovation, as we seek to become successful, produce solutions that patients require, and make those accessible to patients in an economically viable and sustainable manner, using channels that have previously not been used, if legally possible. We are strengthening our portfolio with new products, particularly high quality and reliable biosimilar products, that will create growth for the company in the future, make a significant impact on people's healing journey and contribute to our mission of "healing lives."To follow up on the many firsts we have achieved since 1912, we are working hard to become the first Turkish pharma company to buy out or become shareholder in a pharma company in USA, as we have in Europe, and develop its own molecule.	<ul style="list-style-type: none">▸ R&D and Innovation▸ Biotech Products▸ Access to Pharmaceuticals▸ Digitization and Big Data Management▸ Stakeholder Relations▸ Pricing	   
		We manufacture all pharmaceuticals using the highest technology, complying with the quality and safety conditions stipulated by all the legal regulations, in particular international standards and intellectual property rights, and offer them to the service of patients.	<ul style="list-style-type: none">▸ Drug Safety and Side Effects▸ Intellectual Property and Patent▸ Access to Pharmaceuticals	
Our Values		Description	Our Related Prioritization Topics	SDGs We Support
WE ARE PASSIONATE	We advance towards the future with enthusiastic and accomplished employees	We are working to create a company where Abdi İbrahim employees can realize their passions, where their ideas are considered in the decision making processes, where they can develop themselves through "up-skill" and "re-skill" training opportunities to gain skills that in the future will be required at individual and company levels and, as such, where they can become part of an organization that creates value for its employees, society and our world.	<ul style="list-style-type: none">▸ Talent Management▸ Employee Satisfaction	   
		We provide a working environment where our employees do not suffer discrimination due to their religion, language, ethnicity, disability or sexual preferences, where the principle of equal pay for equal work is implemented, and where a culture of diversity prevails among employees.	<ul style="list-style-type: none">▸ Inclusion and Diversity▸ Gender Equality▸ Human Rights▸ Talent Management	
	We strive to be a leader in occupational health and workplace safety	We strive to create working conditions that are in accordance with the applicable legal regulations and international standards on occupational health, workplace safety, preventive measures and workplace hygiene and support our employees on these issues by providing training opportunities and company-wide practices, volunteering activities and initiatives.	<ul style="list-style-type: none">▸ Employee Satisfaction▸ Human Rights▸ Occupational Health and Workplace Safety	

VISION 2025, Abdi Ibrahim's strategic roadmap, is directly related to the company's basic sustainable development mission. Thanks to its economic activities, the gross added value created by Abdi Ibrahim **has reached 645 million dollars**.

SOCIOECONOMIC CONTRIBUTIONS		HUMAN DEVELOPMENT					RESOURCE USE		GOVERNANCE AND INFRASTRUCTURE	
		3 GOOD HEALTH AND WELL-BEING	4 QUALITY EDUCATION	5 GENDER EQUALITY	8 DECENT WORK AND ECONOMIC GROWTH	10 REDUCED INEQUALITIES	12 RESPONSIBLE CONSUMPTION AND PRODUCTION	13 CLIMATE ACTION	9 INDUSTRY, INNOVATION AND INFRASTRUCTURE	17 PARTNERSHIPS FOR THE GOALS
ECONOMIC DEVELOPMENT	645 million dollars Total gross added value created									
	› 20 thousand people Total employer contribution									
	› 25 million dollars Direct tax contribution									
	› 100 million dollars Exports to more than 60 countries									
	› 70 million dollars Attracted foreign direct investment									
	› 45 million dollars Public savings from first generics									
HOLISTIC HEALTHCARE	21 products developed in the field of preventive medicine									
	Licensing partnership with over 30 companies									
	Access provided through localization of the value chain									
	Activity in 128 therapeutic areas									
	Person-days spent in good health due to our products are equivalent to 15 million years									

SOCIOECONOMIC CONTRIBUTIONS

SOCIOECONOMIC CONTRIBUTIONS		HUMAN DEVELOPMENT					RESOURCE USE		GOVERNANCE AND INFRASTRUCTURE	
										
DISRUPTIVE INNOVATION	45 startups enabled by digital transformation									
	8 million dollars investment for R&D studies undertaken by 127 scientists									
	Investments in OM Pharma and Ocugen									
	Partnerships with local and international institutions									
	Biotech drug production facility AbdiBio									
	mRNA and inactivated vaccine production capability									
PUBLIC COMMITMENT	Goal to become carbon neutral by 2030									
	Increasing personal health awareness									
	Scientific awareness initiatives									
	Social innovation programs									
	Volunteering activities									

PROFILE

Turkey's unlimited "healing power"

With experience spanning more than a century, Abdi İbrahim is one of the most well-established and strongest industrial organizations in Turkey. It also continues with its investments and breakthroughs in international markets, and is progressing with determination towards its goal of ranking among the top 100 pharma companies in the world.



Abdi İbrahim in a Nutshell

Abdi İbrahim, the leader of the Turkish pharmaceutical industry, aims to make its innovative and pioneering momentum sustainable by drawing power from its deep-rooted corporate values.

The foundations of Abdi İbrahim were laid in 1912, in a small pharmacy founded by Pharmacist Abdi Nadir İbrahim Bey, located in the Küçükmustafapaşa district of Istanbul. The journey of "healing," which started with the medicine produced here, continued in the laboratories in Mahmutpaşa and Çemberlitaş districts and the factory in Vefa.

Abdi İbrahim has been operating in Turkey's most modern and high-tech production facilities in Esenyurt since 1996.



You can find the corporate promotional film [here](#).



Production facilities in three countries



403 products



520 million annual production capacity



Exports to more than 60 countries



4,452 employees



Collaboration with nearly 30 licensors



193 brands



Abdi İbrahim teams operating in 15 countries



A value increasing at a global scale

Abdi İbrahim, in taking its success to international platforms and expanding its service network day by day, established in 2012, as part of its worldwide growth strategy, the Abdi İbrahim Global Pharm (AİGP) in Kazakhstan--the most modern pharmaceutical industry factory investment in the country. Founding Abdi İbrahim Otsuka (AİÖ) with Japan's giant pharma company Otsuka in the same year, the Company established Abdi İbrahim Remede Pharma (AIRP) in Algeria in 2014, realizing the most modern pharmaceutical industry factory investment in the country. The production facilities in Kazakhstan and Algeria became operational in 2015 and 2017, respectively.

Taking a historic step towards becoming a strong international player in 2020, Abdi İbrahim acquired OM Pharma, an 83-year old pharma company of the pharmaceutical industry leader, Switzerland, with a Swiss joint venture group. With this step taken to increase its effectiveness in international markets and to become more assertive in the field of biotechnology, Abdi İbrahim became the first Turkish pharma company to have a say in the management of a European pharma company.

Abdi İbrahim is an international licensor, providing licenses to many countries, including those that are home to companies occupying significant places in the world pharmaceutical industry today, and operates in Kazakhstan, Algeria, Georgia, Germany, Azerbaijan, Bosnia-Herzegovina, Albania, Iraq, Tunisia, Saudi Arabia, United Arab Emirates, Kosovo, North Macedonia and Portugal with its own organizational structure. Its growth in international markets continues with exports to more than 60 countries in Europe, North America, Africa and Asia.




The largest brand and product portfolio in the industry

In addition to working with nearly 30 licensors, Abdi İbrahim develops its own products and has the widest brand and product portfolio in the industry. It provides services in the fields of oncology, gastroenterology, cardiology, neurology, respiratory, urology, metabolism and endocrinology, dermatology, rheumatology, nervous system, hematology, infectious diseases and ophthalmology, as well as supplements, cosmetics and medical devices.

Pharma company with the highest employment

Abdi İbrahim boasts the largest marketing-sales department in the sector, as well as being the pharma company with the highest employment. The environmentally friendly working model is evident in the ISO 14001 Environment Management System Certificate of the Company which attaches great importance to occupational health and safety in work procedures, and takes utmost care to comply with relevant legislation as well as ISO 45001 and other international standards.



Setting worldwide examples with buildings incorporating art

Abdi İbrahim's Esenyurt Production Complex, which began operating in Istanbul in 1996, was designed by the famous Italian architect Dante Benini, who is regarded as a doyen in the design of industrial buildings and pharmaceutical production facilities. Abdi İbrahim Tower in Maslak, the headquarters of the company, was also designed by Dante Benini and commissioned in 2007. The exemplar buildings are equipped with environmentally friendly smart technologies and sculptures, videos, installations and paintings by many artists, from Turkey and overseas, are exhibited.



You can access the virtual tour video of Abdi İbrahim Tower [here](#).



Vision

We, as the leading Turkish pharmaceutical company, work passionately to heal the lives we touch, to be a strong international brand with innovative products and services through brave and pioneering initiatives.

Corporate Values

We are courageous

Because we approach the future fearlessly to explore the unexplored and to do the undone.

We are passionate

Because we are conscious that making lives better is only possible through producing good jobs with passionate people.

We are responsible

Because we are aware that each one of us has an impact on those around us, and are responsible for a healthier society and a world worth living in.



Milestones

1912

The first pharmacy was established in the Küçükmustafapaşa district of Istanbul by pharmacist Abdi Nadir İbrahim Bey.

1916

Production of "proprietary medicine" started in the pharmacy: Strength Syrup, Abdi İbrahim Laxative Sugar, Bromo-Valerin Nadir

1919

The first drug production factory was established and ready-made drug production started for the first time.

1940

Under Pharmacist İbrahim Hayri Barut, the second generation assumes management.

1953

Laboratories moved to Vefa district.

1975

Became a joint stock company and took its present name thanks to the contributions of Ahmet Kamil Esirtgen, spouse of shareholder Nesrin Barut Esirtgen.

1981

Under the Pharmacist Nezi̇h Barut, the third generation took over the management.

1996

The Esenyurt Production Complex, incorporating cGMP (current Good Manufacturing Practices) standards, became operational.

2002

Sector leadership in unit sales achieved.

2003

Sector leadership achieved in turnover and unit sales.

2007

Abdi İbrahim became the first Turkish company to rank among the "World's Top 100 Pharma Companies".

The Abdi İbrahim Primary School was opened.

Abdi İbrahim Tower building entered service.

2008

The first pharmaceutical R&D Center accredited by the Ministry of Science, Technology and Industry was opened.

The corporate identity has been renewed.

2010

Abdi İbrahim Logistics Center put into service in Esenyurt, Istanbul.

Abdi Farma company established in Portugal.

2012

With the acquisition of 60 percent of Global Pharm, Abdi İbrahim Global Pharm (AİGP), one of the biggest companies of Kazakhstan was established, and the factory investment began.

Abdi İbrahim Otsuka (AİO) was established in Turkey on a 50 percent partnership structure with the Japanese company Otsuka Pharmaceutical.

2014

Abdi İbrahim Remede Pharma (AIRP) was established in Algeria and the factory investment began.

2015

The renovation project was realized for Sultan II. Bayezid Edirne Dârüşşifası (Sultan Bayezid II Edirne Dar Al Shifa)

Abdi İbrahim Global Pharm, the production facility in Kazakhstan, became operational.

2017

The most modern production facility in Algeria Abdi İbrahim Remede Pharma started production.

The construction of the Sterile Ophthalmology Production Facilities and Sterile Inhalation Facilities along with the Hormone Production Facility began.

2018

An opening ceremony was held for the AbdiBio Biotechnological Pharmaceutical Production Facility and a groundbreaking ceremony for the Sterile Injectable and Oncology Production Facilities.

The Hormone Production Facility started operating.

The license for Abdi İbrahim's first biosimilar product in Turkey was obtained.

ISO 13485:2016 certificate obtained for wound dressing.



You can access the Milestones movie here.

2019 and 2020 Developments

After two productive and successful years

Abdi İbrahim, which has taken important steps in terms of production, investment and employment, as well as sustainability in both Turkey and international markets, has made ambitious moves that will inspire all companies in 2019 and 2020.



Josef Troxler
CEO of OM Pharma



Since the acquisition of our company on October 1st 2020, OM Pharma is very pleased to count Abdi İbrahim as strategic partner. A collaboration initiative has started in March 2021 to explore possible synergies between both companies. This initiative has already enabled the launch of concrete projects. The entire OM Pharma team has started this new collaboration highly motivated and sincerely believe this is only the beginning of a long and fruitful relationship.

The first Turkish pharma company to have a say in the management of a European pharma company

Taking a historic step towards becoming a strong international player, Abdi İbrahim acquired OM Pharma, an 83-year pharma company of the pharmaceutical industry leader Switzerland, with a Swiss joint venture group. Purchasing 28.5 percent of OM Pharma shares at 500 million Swiss francs (approximately TRY 4.2 billion), Abdi İbrahim became the sole foreign partner in the group. This development resonated heavily in the press.



You can access the OM Pharma acquisition movie [here](#).



The first Turkish pharma company to sign the CEO Water Mandate

Abdi İbrahim attaches great importance to the efficient use of water and the protection of water resources, among the most precious legacies for life. This awareness has led to Abdi İbrahim becoming the first Turkish pharma company to join the signatories of the CEO Water Mandate, a United Nations Global Compact (UNGC) initiative, in January 2020. In this context, Abdi İbrahim, which is committed to supporting sustainable water policies and practices globally, leads the pharmaceutical industry in this respect as well.



The CEO Water Mandate

The first Turkish pharma company to sign SBTi

Abdi İbrahim became the first signatory of the Science Based Targets initiative (SBTi) in the Turkish pharmaceutical industry, introducing yet another feat to our sustainability efforts. In this context, Abdi İbrahim will again set targets to create a greenhouse gas emission reduction roadmap.



SCIENCE
BASED
TARGETS

DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

International success in climate change management

Regarding sustainability and energy efficiency as important issues, Abdi İbrahim has reported its efforts in water management as well as climate change management for the first time under the Carbon Disclosure Project (CDP) Climate Change and Water Security Programs. With this report, we have made it onto the B- list by ranking above the general average in the global level in Biotechnology & Pharmaceutical Industry under the Climate Change Program. As a result, the company has achieved notable success in the Carbon Disclosure Project, which includes approximately 10,000 companies from all over the world and has the largest worldwide environmental database.



More than 40 awards in two years

Abdi İbrahim was deemed worthy of 44 national and international awards in 2019 and 2020 with its successful and innovative works, the projects it has implemented, and its performance.



You can access
the awards page here.

The first Turkish company to sign the Recover Better declaration

Abdi İbrahim was among the 155 global companies that signed the "Recover Better" statement, which was established under the leadership of the United Nations and the Science Based Targets initiative. Abdi İbrahim is the first and only Turkish signatory of this entity, which has been established to ensure the continuity of improvements in climate change, due to decreased human mobility during the fight against the COVID-19 pandemic. In this way, the company will establish targets to create a roadmap aimed at reducing greenhouse gas emissions.

**RECOVER
BETTER.**



Renewable energy move

Abdi İbrahim intends to bring its carbon footprint to zero in 2030, and has implemented a practice which is a first in the pharmaceutical industry. As of January 1, 2020, it has become the first Turkish pharma company to transition to 100 percent renewable energy by meeting the electricity needs of all production facilities in its Esenyurt Production Complex in Istanbul from solar and wind power plants. Its energy consumption in the production complex was 44,209,606 kilowatt hours in the year 2020, an energy consumption equivalent to the yearly electricity consumption of 26,000 houses, met from renewable sources. With this practice, it has prevented carbon emissions equivalent to the use of 5,230 vehicles over the course of a year. Thus, the carbon footprint was reduced by approximately 24,000 tons of CO₂ equivalent.

100 percent renewable energy

44,209,606
kilowatt hours of energy

An amount of energy equivalent to the yearly electricity consumption of 26,000 houses was met from renewable sources

Carbon emissions equivalent to the yearly release of 5,230 vehicles have been prevented

The carbon footprint was reduced by approximately **24,000 tons of CO₂** equivalent



Turkey ranks second in Europe after Germany in terms of the use of renewable energy sources and is constantly developing in this field. This parallel between national energy policies and Abdi İbrahim is extremely uplifting. The use of renewable energy is prestigious for companies, and the recently published RES-G legislation has come into force for certification on this matter. By reducing its carbon emissions, Abdi İbrahim is making a positive contribution with regard to global warming, one of the world's major problems.



Onur Ece
Enerjisa Sales Leader
(Private Customers)

COVID-19 Pandemic Actions

Abdi İbrahim's commendable measures in the fight against coronavirus

In the process of the fight against COVID-19, which has led to sudden and drastic changes all over the world, Abdi İbrahim put its R&D and production teams, medical capabilities, and all its expertise and experience at the disposal of Turkish medicine and patients, while also implementing exemplary projects within the company.



Hasan Düzova
Esenyurt Production
Complex, Solid Product
Manufacturing
Tablet Press Operator

Although the process of combatting COVID-19 and the restrictions it imposed were very challenging at first, we stood together as those who improve life through healing. We continue to work day and night with all our strength for the uninterrupted production and delivery to patients of the necessary medicines.



Photograph: AA

Abdi İbrahim has moved proactively to mobilize against the pandemic, implementing the Campaign to Contribute towards the Fight Against COVID-19. It has manufactured and donated to the Ministry of Health the medicine among its products that has proven to be effective in the treatment of COVID-19 and became part of the treatment protocol.

With the support of the Ministry of Foreign Affairs and the Ministry of Commerce, Abdi İbrahim immediately procured the raw material necessary for the drug used in the COVID-19 treatment protocol, which has seen a huge increase in demand, and went on to produce and donate 1.6 million tablets to the Ministry of Health. Until the end of 2020, the remaining output of this medicine was made available to the Turkish healthcare system through donations.

Using all the means in its disposal to end the national threat posed by the virus as quickly as possible, Abdi İbrahim has made a commendable contribution, through the uninterrupted production and supply of the medicine. It has also provided international support through the donation of over 250,000 tablets to Kazakhstan and Algeria, where its factories are located.



You can access the film [Contribution to the Fight Against COVID-19](#) here.

"3D Support" from Abdi İbrahim

Abdi İbrahim has taken part in the "3D Support" initiative launched across Turkey to support healthcare professionals in the fight against coronavirus, by producing the consumables needed in the treatment procedures of patients using 3D printing. Abdi İbrahim supported this important initiative by producing protective masks with the 3D printer in the R&D Center.

Vaccine production permit for Abdi İbrahim

Abdi İbrahim, which also has an important responsibility in the field of vaccines, received the production and filling permit in December 2020, certifying its capacity to produce COVID-19 vaccines to the highest standards. As a result of the examinations and inspections carried out by the Ministry of Health, Abdi İbrahim was granted a license for the manufacture and vial-filling of human vaccines for mRNA-based or inactivated vaccines.

Digital communication platform Microsoft Teams

Abdi İbrahim attaches great importance to digitalization, which has become indispensable around the world. The company had made significant investments in this regard, with 85% of its business procedures having already been digitized by the time pandemic hit. Abdi İbrahim completed the introduction of Microsoft Teams, the company's digital communication platform, at the beginning of the pandemic and made it available to employees. The company was able to manage the process in a healthy and effective way, thanks to these investments.

Viral Gundem (Viral Agenda) project

During the COVID-19 pandemic, up-to-date medical information was in very high demand. At this point, Abdi İbrahim Medical Affairs Directorship took the initiative and prepared the Viral Gundem (Viral Agenda) project in April 2020. The Viral Gundem (Viral Agenda) bulletin, which includes up-to-date and evidence-based medical information, entered circulation via e-mail among KVKK-approved healthcare professionals, at regular intervals. It was met with great interest, achieving high reading levels. The publication, which is far ahead of its peers in terms of sustainability and content production, continues to reach a wide audience via Abdi İbrahim's social media accounts.

With the "Viral Agenda" project, which meets a need during the pandemic period, our aim is to convey current scientific information based on evidence, concisely and clearly, to everyone but primarily to healthcare professionals. We work with the meticulousness of a jeweler at every stage, from article selection to control, from the design to the evaluation of final reports. This project is good example for sustainability, in terms of its undisrupted continuity, and we will be keeping the project alive even after the pandemic has passed, by incorporating the entire field of medicine.

Abdi İbrahim, Viral Gundem (Viral Agenda) Team



"Health to Your Home" for Abdi İbrahim Employees

As part of the measures taken against the COVID-19 epidemic, a successful communication project called "Evine Sağlık" -- "Health to Your Home" -- was implemented within the company, during the time in which Abdi İbrahim employees were working from home. The Health to Your Home program, which provides opportunities for employees to increase their productivity, support each other, and stay fit both physically and mentally while at home, began on March 30, 2020. Live broadcasts are part of the program, which hosted company employees or volunteer guest experts on subjects such as healthy living, psychology, family communication, hobbies, skills, and personal development, attracted much attention from Abdi İbrahim employees.

Our aim with the Health to Your Home internal communication project was to maintain spiritual integrity and personal development, while keeping the the employees' psychology in balance, in order to adapt to the "New Normal" during this grim COVID-19 period. In this way, we have implemented this project on the basis of the balance model based on mental, physical and spiritual health. We are very pleased to see that we stand in unison and solidarity during such a period and are able to contribute to this project.


Abdi İbrahim, Health to Your Home Team



A first for Abdi İbrahim: digital disease management

Attaching great importance to digitalization, Abdi İbrahim offers robust support to the Turkish pharmaceutical industry with its effective projects. Abdi İbrahim Otsuka broke new ground by implementing the telemedicine system, highlighting the importance of remote health technologies in the fight against the COVID-19 epidemic. Community Mental Health Center (TRSM) employees can undertake occupational therapy, patient interviews and group psychotherapies remotely to their clients through this system.

Abdi İbrahim also implemented the hematology oncology telemedicine project during the course of the pandemic. The project, which is handled as an end-to-end digital disease management and telemedicine study in the field of hematology and oncology, enables patients to manage their treatments and make online video calls with their physicians whenever they want. The patient journey begins with the physician inviting the patient by way of the system. The patient downloads the "Albert Health Assistant" mobile application via the SMS received, gives the necessary permissions, and registers. With this method, the patient can very quickly establish a closed-circuit communication network with their physician. Through this system, which is fully compliant with the GDPR and hosted in servers in Turkey, the patient can set up medication reminders, record their measurements, store their documents and have an online video call with their physician whenever they want. For the second phase of the project, Albert Health Assistant and Albert Web Platform are planned to be customized for the field of oncology and hematology, thereby increasing the benefits it provides to patients and doctors.

 p.39 You can find the awards received for the projects undertaken by Abdi İbrahim during the pandemic process here.

MANAGEMENT

A corporate culture integrated into ethics, transparency, risk and compliance processes

Abdi Ibrahim wishes to pay its debt to its homeland by investing, producing, exporting and creating employment; and acts with an approach that respects human dignity, is comprehensive, ethical and responsible in its operations.



Key Performance Indicators (KPI)

	Maintain leadership in the Turkish pharmaceutical market	2019 market share → US dollars	6.15%	2020 market share → US Dollars	6.05%
	To expand in international markets	by the end of 2020 Exports to more than 60 countries			Rate of increase in international sales in 2020 in comparison to 2018 → ↑ 10%
	To preserve a strong brand reputation	In the Corporate Perception and Reputation Survey that concluded in 2019, it was chosen by many stakeholders as the most well known and respected company in the sector.			
	An innovative approach to investment	Notable investments in 2019 and 2020 →	Bought out the pharma company Swiss OM Pharma with a Swiss joint venture group.	Realized a Biotechnological Product Development Laboratory investment within AbdiBio.	Sterile Ophthalmology and Sterile Inhalation Facilities began production.
	Support for national and international platforms	Number of platforms and initiatives participated in and supported →	34		

Management Strategy


Adopting an innovative management approach in order to make its leading position in the sector sustainable, Abdi İbrahim is taking confident steps towards its goals through its long-term strategic plans and rapid actions in response to opportunities and threats.

Founded in 1912 by Abdi Nadir İbrahim Bey, Abdi İbrahim San. Tic. A.Ş. is managed by the Board of Directors with Phar. Nezih Barut as the Chairman, representing the third generation of the family. Abdi İbrahim's 100 percent domestic capital is divided within the partnership structure of the Barut and Esirtgen families, each holding 50%, making it a family company with a successful corporate structure.

Abdi İbrahim, which has been pursuing extensive goals and far-reaching ideals since the day of its foundation, always makes long-term strategic plans and carries out all its activities with a three-dimensional perspective. With this understanding, in 2014 it realized

the "POWER-AI Strategy Vision Project" and focused on five main areas of growth: "existing products, new products, international markets, production services, acquisitions and new partnerships." In the five-year period, it has improved its business processes under POWER-AI, implemented many projects and made significant progress in its areas of growth. Further reinforcing its strength every year, Abdi İbrahim achieved a 59% rate of growth in dollars from 2015 to 2020.

Having successfully implemented the POWER-AI process in 2020, Abdi İbrahim launched its new strategic plan, VISION 2025, in January 2021. Under VISION 2025 designed with the motto of "Becoming the healing power of the changing world", there are eight strategic programs and 45 initiatives that will enable Abdi İbrahim to reach its desired targets within the five-year period.



Abdi İbrahim has been pursuing great objectives and great ideals for the entirety of its 109 year history since its foundation, and this year has not been any different. Our experience of 109 years, our respect and care for what we do, and our capabilities afforded by our assertiveness have been the drivers of our success. 2021 marks the first year in our next five-year period. Beginnings are important and valuable. I firmly believe that we will be off to a good start and preserve that momentum throughout the period. We'll maintain our sensitive and diligent attitude regarding our world, sector, people and society. We'll pursue great objectives not only in Turkey, but with all our employees in our countries of operation. We'll continue to put in the work required of a pioneer and a leader.

Abdi İbrahim Board of Directors




Phar. Nezih Barut
Chairman



Ahmet Kamil Esirtgen
Member of the
Board of Directors



İbrahim Barut
Member of the
Board of Directors



Nesrin Barut Esirtgen
Deputy Chairman



Ahmet Cenan Esirtgen
Member of the
Board of Directors and
Executive Board



Hasan Akçakayalıoğlu
Member of the
Board of Directors

Environmental Goals



To take steps in reducing carbon emissions across the entire value chain as part of the Organizational Life Assessment Analysis (O-LCA).



To ensure the efficient use of all natural resources, especially water resources.



To promote the use of packaging materials that are less harmful to the environment, instead of packaging with plastic.



To take important steps in waste management.



To organize training activities aimed at raising the environmental protection awareness of employees, all third party companies and relevant parties.



To use appropriate technology to control and minimize potential impacts on the environment.



To follow and comply with legal, international legislation and customer requirements in order to prevent environmental pollution, and to continuously improve environmental performance.



To continue taking steps to protect biodiversity.



To become one of the environmental sustainability leaders.



Social Goals



To provide the public with accurate information in the field of medicine and health.



To ensure the access of disadvantaged groups to pharmaceuticals and health services.



To increase science awareness in the country.



To support social innovation in health.



To lead innovations in the health sector.



To provide an environment and atmosphere of passionate work for human resources.



Excellence in talent acquisition and management.



To promote gender equality, women's employment and equal opportunities.



To establish and maintain the performance and corporate culture associated with strategic priorities.



To develop the competencies and skills envisaged by the strategy.



To create the system and sustainable processes required by the HR infrastructure.



Create a safe work environment by taking into consideration the health and safety risks that may arise from potential dangers and activities in the workplace; to identify protection parameters and implement them.



To organize training activities for employees, suppliers and subcontractors, aimed at the effective fulfillment of their occupational health and safety practices.



Management Goals



To continue healing lives by developing new products.




To maintain market leadership while remaining profitable in Turkey.



To become an established player in developed markets.



To expand in international markets and increase the share of foreign revenues in the total figure.



To make Turkey one of the major production bases of production services in Europe.



To be able to develop own biotechnological pharmaceuticals.



To be one of the 10 most respected companies in Turkey by preserving a strong brand reputation and creating value for employees.



To make the integrated corporate culture sustainable in ethics, transparency, risk and compliance processes.


Company Policies

Attaching great importance to company policies in sustainable success, Abdi İbrahim continues to work in line with national and international standards.

p.87

You can find Abdi İbrahim's company policies here.

Organizational Structure



Business Ethics Principles

Abdi İbrahim Ethics Principles reflect the company's commitment and commitment to basic business conduct and business ethics principles within the scope of its responsibilities towards all its stakeholders.

Acting since 1912 with the awareness that human health is the most basic and primary responsibility, Abdi İbrahim believes in the importance of fulfilling its tasks in a thorough, proper and honest manner, and in this way always sets the highest standards. With this approach, the Company wishes to carry the trust and respect of its stakeholders into the future, and considers it one of its greatest responsibilities to remain faithful to its guiding ethical principles in all business procedures.

Abdi İbrahim manufactures all of its products by using the most advanced technology, meeting the quality and safety conditions stipulated by all legal regulations –in particular international standards and intellectual property– and offers them to the service of the people, while maintaining the principles of ethics and transparency in all business processes.

Considering product safety as one of its integral principles, Abdi İbrahim's pharmacovigilance system and cGMP approved production facilities are audited by national and international health authorities and companies. Each of the Company's audits in the years 2019 and 2020 were concluded successfully.

| GRI | 102-16 | 102-17 |



You can access Abdi İbrahim Business Ethics Principles here.

Abdi İbrahim's Ethical Behavior Principles

Impartiality

Honesty

Reliability

Transparency

Social benefit and respect for the environment

Information security

Internal Audit Practices

The Internal Audit Directorate, which operates independently and impartially within Abdi İbrahim, audits the effectiveness, efficiency and compliance with the legal regulations of all the activities in the Company.

Abdi İbrahim Internal Audit Directorate, which has been operating since 2006, continues to work in line with the Audit Committee Regulation and the Internal Audit Regulation; and is focused on adding value to risk management, control and governance procedures.

Internal and external control, early warning and auditing activities are of strategic importance for Abdi İbrahim, which considers social norms and Business Ethics Principles as well as legal regulations in all business procedures. In this context, meticulous attention is also given to the fight against corruption and bribery. Abdi İbrahim fights against possible corruption and bribery cases in internal and external business procedures on the basis of accountability, transparency criteria and ethical values; avoids all kinds of financial dependence in its business relations, and accurately and thoroughly informs the institutions it cooperates with, and the public regarding its financial and operational data.

Abdi İbrahim has an elevated reputation in the eyes of the public, thanks to its well established corporate culture, and no corruption or bribery cases were experienced during the reporting period.

| GRI | 205-1 |

Reputation Management

Abdi İbrahim continues its activities within the framework of its vision and corporate values, so as to preserve its well established corporate culture and reputation, which has been created with more than 100 years of experience and expertise.

Abdi İbrahim maintains a constant focus on maintaining high quality in its products. In this context, all R&D studies and clinical researches for product development are carried out in the light of medical ethics and within the framework of international regulations, as well as national legislation. Abdi İbrahim, which has achieved a high reputation and results in many researches thanks to this approach and its work on reputation management, carried out the Corporate Perception and Reputation Survey in 2019 with a sample of 3,500 for all its stakeholders, including its overseas employees. According to the research, many stakeholders consider it to be the most well-known and most admired company in the sector.

Abdi İbrahim was chosen as the most well-known and respected company in the sector by many stakeholders in the Corporate Perception and Reputation Survey undertaken in 2019 with a sample size of 3,500.

Stakeholder Relationship Management

| GRI | 102-40 |

Believing in the importance and influence of stakeholders in progress in the field of sustainability, Abdi İbrahim communicates effectively with all its internal and external stakeholders and shapes its work in line with the feedback it receives.

Abdi İbrahim, which regularly communicates and cooperates with all its stakeholders, from employees to end consumers, from physicians to pharmacists, from non-governmental organizations to licensors, attaches great importance to meeting the expectations and priorities of its stakeholders and takes them into account in all business procedures.

Abdi İbrahim's stakeholder map and communication channels can be found on the right.



Corporate Memberships and Supported Initiatives

Believing in the importance and power of non-governmental organizations, Abdi İbrahim takes an active role in platforms such as national and international trade unions, chambers and associations operating in different fields.

<p>Foreign Economic Relations Board</p>  <p>DEİK DİŞ EKONOMİK İLİŞKİLER KURULU FOREIGN ECONOMIC RELATIONS BOARD</p>	<p>Turkey Exporters Assembly</p>  <p>TİM TÜRKİYE İHRACATÇI MECLİSİ</p>	<p>Istanbul Chamber of Commerce</p>  <p>İSTANBUL TİCARET ODASI 1882</p>	<p>Public Communication and Corporate Relations Management Association</p>  <p>KİYED</p>	<p>Cosmetics and Cleaning Products Manufacturers Association</p>  <p>KİT KOSMETİK VE TEMİZLİK ÜRÜNLERİ YARATICI VE TİCARETİ KURULUŞU</p>	<p>Women's Empowerment Principles (WEPS)</p> <p>WOMEN'S EMPOWERMENT PRINCIPLES</p>	<p>Science Based Targets Initiative (SBTi)</p>  <p>SCIENCE BASED TARGETS DRIVING AMBITIOUS CORPORATE CLIMATE ACTION</p>
<p>Union of Chambers and Commodity Exchanges of Turkey</p>  <p>TOBB</p>	<p>Istanbul Chemicals and Chemical Products Exporters Association</p>  <p>İKMİB İstanbul Kimyevi Maddeler ve Mamulleri İhracatçıları Birliği Istanbul Chemicals and Chemical Products Exporters Association</p>	<p>People Management Association of Turkey</p>  <p>İPERYÖN TÜRKİYE İNSAN YÖNETİMİ DERNEĞİ</p>	<p>ISPE, The International Society for Pharmaceutical Engineering</p>  <p>ISPE Connecting Pharmaceutical Knowledge</p>	<p>Marmara Medical Device Manufacturers and Suppliers Association</p>  <p>MAOİAD MARMARA TIBBİ CİHAZ ÜRETİCİ VE TEDARİKÇİLERİ DERNEĞİ</p>	<p>Business World and Sustainable Development Association</p>  <p>skdTürkiye</p>	<p>Recover Better</p>  <p>RECOVER BETTER.</p>
<p>GS1 Organization for the Global Language of Business</p>  <p>GS1 Türkiye</p>	<p>Istanbul Minerals and Metals Exporters' Association</p>  <p>İMMİB İstanbul Maden ve Metaller İhracatçıları Birliği</p>	<p>Turkish Industry and Business Association</p>  <p>TUSİAD</p>	<p>Environmental Protection and Packaging Waste Recovery Foundation</p>  <p>ÇEVKO ÇEVRE KORUMA VE AMBALAJ ATIKLARIN DÖNÜŞÜMÜNE YAKIN</p>	<p>Swiss Chamber of Commerce</p>  <p>TR-CH TÜRKİYE İHRACATÇI VE İHRACATÇI KURULUŞU</p>	<p>Business Plastics Initiative</p>  <p>İpg İŞ DÜNYASI PLASTİK GİRİŞİMİ</p>	<p>Turkey Circular Economy Platform</p>  <p>Turkey Circular Economy Platform</p>
<p>Pharmaceutical Industry Employers Association</p>  <p>İEİS İLAÇ ENDÜSTRİSİ İHRACATÇILARI DERNEĞİ</p>	<p>Istanbul Chamber of Industry</p>  <p>İSO</p>	<p>Turkey Training and Development Platform</p>  <p>İGEP Gelişimin Paydaşı Ol</p>	<p>Corporate Communicators Association</p>  <p>KİD KURUMSAL İLETİŞİM DERNEĞİ</p>	<p>UN Global Compact (UNGC)</p>  <p>THE GLOBAL COMPACT WE SUPPORT</p>	<p>Carbon Disclosure Project (CDP)</p>  <p>CDP DRIVING SUSTAINABLE ECONOMIES</p>	<p>Turkey Materials Marketplace</p>  <p>Türkiye materials marketplace</p>
<p>Istanbul Exporters' Associations General Secretariat</p>  <p>İİB</p>	<p>Istanbul Commodity Exchange</p>  <p>İSTANBUL TİCARET BORSASI İSTANBUL COMMODITY EXCHANGE 1924</p>	<p>Corporate Governance Association of Turkey</p>  <p>Türkiye Kurumsal Yönetim Derneği</p>	<p>All Food Foreign Trade Association</p>  <p>TUGİDER TÜRK GIDA DIŞ TİCARET DERNEĞİ</p>	<p>Global Reporting Initiative (GRI)</p>  <p>GRI</p>	<p>UNGC CEO Water Mandate</p>  <p>UN GLOBAL COMPACT CEO WATER MANDATE</p>	

Awards and Achievements

With its successful and innovative work, the projects it implemented and its performance, in 2019 and 2020 Abdi İbrahim was deemed worthy of many national and international awards.

2019 →

Abdi İbrahim among the Good Life Brands

In the "Good Life Brands 2019" organized by Nielsen for Sustainable Brands Istanbul, according to consumers, Abdi İbrahim was among the top five companies in the health sector.

Award for Abdi İbrahim's R&D poster

Abdi İbrahim R&D team won the third place award with its poster, "Alcohol-Induced Dose Dumping Studies in Gastro-resistant Hard Gelatine Capsules Containing Immunosuppressant Drug" at the 7th International Pharmaceutical Chemistry Conference.

İksir Program wins first place in the drug category

Abdi İbrahim İksir Young Talent Development Program ranked first in the pharmaceutical category of the Top100 Talent Program 2019 list compiled by Toptalent. On the overall ranking, it placed 15th.

Abdi İbrahim at the top again in R&D 250

In the 2018 R&D 250 list, prepared by the magazine Turkishtime in cooperation with Turkish Exporters' Association, Abdi İbrahim was in the top three in sector category, and highly placed in the seven other categories.



İksir Program wins first place in the drug category

Abdi İbrahim İksir Young Talent Development Program ranked first in the pharmaceutical category of the Top100 Talent Program 2019 list compiled by Toptalent. On the overall ranking, it placed 15th.

Mustafa Darman, one of Turkey's 50 Most Influential CFOs

In the research conducted in the collaboration between Fortune Turkey and DataExpert, as part of the CFO 2019 Summit, the Abdi İbrahim Finance Deputy General Manager Mustafa Darman was chosen as one of Turkey's 50 Most Influential CFOs.

Hakan Onel, one of the "50 Most Influential HR Managers"

Abdi İbrahim Human Resources Assistant General Manager Hakan Onel was selected as one of the "50 Most Effective Human Resources Managers" in the research organized under the CHRO Summit 2019.

Abdi İbrahim among the "Favorite Companies"

Abdi İbrahim won the second place award in the pharmaceutical industry category at the "Most Popular Companies Awards" organized as part of the Employer Brand Summit 2019, which brings together employers from Turkey and around the world.



Abdi İbrahim among Turkey's industrial giants

Abdi İbrahim has risen by 37 places in the ranking compared to the previous year to place it at 97 –and first in the pharmaceutical industry– in the 2018 "Turkey's Top 500 Industrial Enterprises" list of the greatest in Turkey, as determined by the Istanbul Chamber of Industry (İSO).

Oral Presentation Award for the wound care dressing clinical study

Prof. Dr. Şevki Çetinkalp presented Abdi İbrahim's innovative wound dressing product in the 41st Turkey Endocrinology and Metabolic Diseases Congress, for which it was awarded third place.

Gold award to Abdi İbrahim in the field of social media

Abdi İbrahim won first prize in the pharmaceutical category at Turkey's first comprehensive social media competition, "Social Media Awards Turkey", which was organized with the cooperation of Marketing Turkey and BoomSonar, supported by the expertise of Deloitte.





Abdi İbrahim among the "Most Attractive Employers"

As in previous years, Abdi İbrahim was selected as one of the most attractive employers in the "Most Attractive Employers Survey 2019" conducted by Universum in Turkey. The research conducted in 50 universities placed it third in the Medicine/Health Sciences category according to students and fourth according to young professionals.

Abdi İbrahim, one of Turkey's largest exporters

Abdi İbrahim ranked 567th in the "2018 Turkey's Top 1000 Exporters" research conducted by the Turkish Exporters Assembly (TİM), rising 30 places compared with the previous year.



Award to Abdi İbrahim R&D Center

The Abdi İbrahim R&D Center was deemed worthy of an award at the Technology and Development Zones and R&D Centers Award Ceremony organized by the Ministry of Industry and Technology.

Abdi İbrahim, the most female-friendly company in the pharmaceutical industry

In the "Women Friendly Companies" research, organized by Capital magazine, Abdi İbrahim ranked 36th in the "100 Woman Manager Friendly Companies" and 52nd on the "100 Women Friendly Companies" list with its contribution to women's employment. Among pharmaceutical companies, it ranked first.

Achievement Award to Ella from Felis

Abdi İbrahim participated in the annual Felis 2019 awards organized by MediaCat with the 360 degree communication campaign prepared for Ella, and was awarded a certificate of achievement in the website sub-category of the health communication category.

Abdi İbrahim again the sector leader in the Capital 500 list

Abdi İbrahim ranked 144th in the "Capital 500-Turkey's Largest 500 Private Companies Survey," rising three places compared to the previous year, and was again ranked first among pharmaceutical companies.

Golden Values Award to Abdi İbrahim

Abdi İbrahim Rx2 General Manager Dr. Oğuz Mülazımoğlu was awarded the Golden Values Award in the 3rd Istanbul Economics Summit.

Abdi İbrahim chosen pharma company of the year

Abdi İbrahim was selected as the Pharma Company of the Year at the Boğaziçi Business World Awards organized by the Boğaziçi University Engineering Club.

2020 →



Pharmaceutical Industry Digitalization Award to Abdi İbrahim

Abdi İbrahim was deemed worthy of the "Pharmaceutical Industry Digitalization Award" at the Platinum Global 100 Awards, carried out under the cooperation of Platin Magazine and Ipsos Research and Consultancy Company.

Abdi İbrahim, again among the greatest in Turkey

Abdi İbrahim ranked 125th in the "Capital 500-Turkey's Largest 500 Private Companies Survey," rising 19 places compared to the previous year, and was again placed first among the pharmaceutical companies.

Platinum Award for Contribution to the Fight Against COVID-19 Campaign

Abdi İbrahim's Campaign to Contribute to the Fight Against COVID-19 was awarded the Platinum Award in the SDG 3 Healthy Individuals Category at the Sustainable Development Goals (SDG) Awards organized by the Corporate Social Responsibility Association of Turkey.



Community Support Award for Contributions to the Fight Against COVID-19 Campaign

The campaign Contribution to the Fight Against COVID-19, carried out by Abdi İbrahim, was deemed worthy of the "Community Support Award" at the Common Future Awards, the first award program dedicated to the fight against COVID-19 in the field of social responsibility organized by the Turkish Confederation of Employers' Unions (TİSK).

Pharma company with the most interaction on social media

According to the analysis made by BoomSocial, the social media measurement platform, on 31 Twitter accounts in the pharmaceutical industry between March 1 and May 24, 2020, Abdi İbrahim was revealed to be the most talked about company in the industry, getting the most interaction among pharmaceutical companies.

Named the most women-friendly pharma company

In the Women Friendly Companies research organized by Capital magazine, Abdi İbrahim ranked 24th in the "100 Woman Manager Friendly Companies" and 53rd in the "100 Women Friendly Companies" list. In the research, it ranked 14th among the companies with the highest increase in the ratio of women employees in the last seven years and 1st among pharmaceutical companies.



Abdi İbrahim entered the top 10 in the Social Media Top 100 List

Abdi İbrahim, which made a great impression in the media with its support campaign against COVID-19, was ranked 7th in the "Social Media Brand Index SocialBrands Turkey May Social Media Top 100 List". It also achieved significant success in the "August Social Media Top 100 List," ranking 60th as the only pharma company in the list.

Mustafa Darman, one of Turkey's 50 Most Influential CFOs

Abdi İbrahim Finance Deputy General Manager Mustafa Darman was selected as one of "Turkey's 50 Most Influential CFOs" in the research conducted as part of the CFO 2020 Summit.

Women Executive Employment Award to Abdi İbrahim

Abdi İbrahim was deemed worthy of the "Women Executive Employment Award" at the Turkish-American Business World Awards (I AmChamPion Awards) organized by the American Companies Association (AmCham Turkey).

Gold Award to Abdi İbrahim

Abdi İbrahim was deemed worthy of the Gold Award in the pharmaceutical category at the Social Media Awards Turkey 2020, organized by Marketing Turkey and BoomSonar.



Selected as the most reliable pharma company

Abdi İbrahim won the "Most Reliable Pharma Company" award at the Trust Istanbul Visionary Awards, where the most reliable brands according to the public are announced.

Abdi İbrahim goes trending on Twitter

In a film published on social media channels on April 3, Abdi İbrahim announced that it had donated its product, which had been demonstrated to be effective in the treatment of COVID-19, to the Ministry of Health. This announcement which resonated across media and social media made Abdi İbrahim trend topic on Twitter.

Abdi İbrahim again among the industrial giants of Turkey

Abdi İbrahim has placed 97th –and first among pharmaceutical companies– in the 2019 "İSO Turkey's Top 500 Industrial Enterprises" list displaying the greatest in Turkey as determined by the Istanbul Chamber of Industry (İSO).



Two gold awards from Stevie Awards to Abdi İbrahim

Abdi İbrahim won two gold awards at the Stevie Awards. In the Career Management Success category, "Regional Manager Selection Process"; and in the category of Most Innovative HR Technology Use in the Pandemic Period-Europe, the "Health to Your Home" internal communication projects of Abdi İbrahim were awarded the Golden Stevie Awards.

Ufuk Güler, One of Turkey's Most Influential Supply Chain Professionals

Abdi İbrahim Supply Chain and Purchasing Director Ufuk Güler was selected as one of the "Most Influential Supply Chain Professionals in Turkey" organized by the Supply Chain Professionals Club (SPC) in partnership with Slimstock and the Logistics Association (LODER).



Ranked among the 50 most innovative companies


Abdi İbrahim was placed among the 50 most innovative companies in the Most Innovative Companies survey conducted in Turkey by Fast Company magazine with its experienced medical sales representative recruitment system called "Talent Radar".

Teams platform becomes a success story at Microsoft

The transition process of Abdi İbrahim to the Microsoft Teams digital communication platform, which it has started to use after completing its launch during the pandemic process, was featured as a success story on Microsoft's global website.

Health to Your Home Project designated as example good practice

At the COVID-19 and Business World webinar organized by the Business World and Sustainable Development Association (SKD Turkey), the Health to Your Home Project, implemented by Abdi İbrahim during the pandemic, was shared with the guests as a good practice example.



Grand Prize from ESOMAR for AiO schizophrenia research

Abdi İbrahim Otsuka's "Survey on the Perception, Level of Knowledge, Stigma and Discrimination Regarding Schizophrenia in Turkey", a first in Turkey, won the first place in the "Making a Difference" category by ESOMAR.

Pharma company with the Most Brand Applications award

Abdi İbrahim, was deemed worthy of the first prize in the category of "pharma company with the highest number of trademark applications" within the scope of the 8th International Pharmaceutical Chemistry Congress R&D Awards. In addition, the poster presented by Abdi İbrahim R&D Department won the third prize.

Poster Presentation First Prize to Abdi İbrahim

Abdi İbrahim Medical Manager Başak Taburoğlu Yılmaz, Bioequivalence Manager Nilden Dayan and Clinical Research Manager Elif Oğralı won the "Poster First Prize" with the "Equivalence Study of Posagil" at the 5th International Congress of Intensive Care Infections.

Golden Mortar Award to Do Not Ignore

Abdi İbrahim Otsuka's "Do Not Ignore - Schizophrenia from Prehistory to the Present" exhibition, which Istanbul residences encountered for the fourth time in May 2019, received the "Social Responsibility" award at the 10th Golden Mortar Awards.



İKSİR Young Talent Development Program in the top 100

Abdi İbrahim's İKSİR Young Talent Development Program succeeded in placing among the TOP100 programs in the TOP100 Talent Program competition organized by the career platform Top Talent.

Abdi İbrahim selected as "Most Attractive Employer"

Abdi İbrahim was selected as one of the most attractive employers in the "Most Attractive Employers Survey 2020" conducted by Universum in Turkey, as in previous years. The research conducted in 55 universities placed it first according to students and third according to young professionals, in the Medicine/ Health Sciences category. In the Science category, it ranked first according to students' opinions and second place with the evaluations of young professionals in the field.



Award for Sustainability Report from LACP Vision Awards

Abdi İbrahim's 2017-2018 Sustainability Report was deemed worthy of three awards at the LACP Vision Awards. The report was evaluated by the League of American Communication Professionals (LACP), and received a Platinum Award in the pharmaceutical industry category along with another in the most creative report category, ranking 16th in the Top 100 among competing reports. In the competition, the summary report was also awarded Platinum.

Award from Istanbul Marketing Awards

Abdi İbrahim Central Nervous System team won the Mention Award at the Istanbul Marketing Awards organized by the Istanbul Marketing Summit; with the website www.pediatricpsychiatry.com and the Mentorship project, which was prepared to provide information on psychiatric problems experienced by children and to share the most up-to-date information to improve the daily routines of physicians.



You can access the 2020 awards movie here.


PERFORMANCE

Activity in international markets rising by the day

As it continues production and investments in its factories in Turkey, Kazakhstan and Algeria, Abdi İbrahim has added momentum to its growth in international markets by purchasing, together with a joint venture group, the 83-year-old Swiss pharma company OM Pharma.



Key Performance Indicators (KPI)

 <p>To accelerate the development of Turkey</p>	<p>Amount of taxes and legal liabilities paid in 2019 and 2020</p> <p>2,113 million TRY</p>	 <p>To increase added value from work procedures through R&D studies</p>	<p>Total R&D spending in 2019 and 2020</p> <p>127.03 million TRY</p>		
 <p>To attain a sales performance that can support future objectives</p>	<p>By the end of 2020</p> <p>Total turnover</p> <p>621.9 million US dollars</p>	<p>Total exports*</p> <p>100 million US dollars</p>	<p>* Total amount of sales made in Turkey and other countries.</p>		
 <p>To enrich product portfolio with reference medication</p>	<p>By the end of 2020</p> <p>193 brands 403 products</p>	 <p>To maintain production quality and pass audits</p>	<p>Esenyurt Production Complex audited and rated as successful by 29 health authorities and clients in the years 2019 and 2020.</p>		
 <p>To develop new products</p>	<p>In 2019 and 2020</p> <p>Licenses and approvals obtained in Turkey →</p>	<p>61 synthetic medicinal product licenses</p>	<p>16 nutrition supplement approvals</p>	<p>25 medical device approvals</p>	<p>9 cosmetic approvals</p>
	<p>44 trademark registration applications in 8 countries</p>	<p>201 licenses in 29 countries</p>	<p>83 trademark registration applications</p>	<p>44 trademark registrations</p>	

GRI

201-1

203-1

203-2

Major Financial and Operational Indicators

Financial and operational success reinforcing industry leadership

Having maintained its industry leadership in Turkey since 2002, Abdi İbrahim performed strongly both in our country and in international markets, despite the fluctuations experienced around the globe in 2019 and 2020.

| GRI | 102-2 | 201-1 | 203-1 | 203-2 |

* Data from January-December 2020 IQVIA Retail Dataview.

** Total amount of sales made in Turkey and other countries.

*** Overseas and subsidiaries are included.



Production

Abdi İbrahim continues to heal lives and the future around the world with its high-tech production facilities in Turkey, Kazakhstan and Algeria, and its R&D investments of nearly 130 million TRY over two years.



Altuğ Uysal

Abdi İbrahim Head of Supply Chain Group

With our new facilities and equipment investments, our production capacity will continue to increase. This is sure to bring new collaborations, know-how accumulation, employment and growth. We will continue to focus on digitalization, analytical decision support mechanisms and efficiency in all our facilities and operations.



Esenyurt Production Complex

ISTANBUL / TURKEY

Having entered service in 1996 with a total indoor area of 83 thousand square meters, and an investment of 100 million dollars, the Esenyurt Production Complex in Istanbul has a production capacity of 450 million units per year. The processes in the facilities, where GMP and GLP requirements are met and modern and environmentally friendly technologies are used, are constantly improved with both technological investments and automation systems that increase traceability and efficiency.

In the facilities where production services are provided to national and international companies with teams numbering more than 1,200; Production is made in solid, semi-solid and liquid forms. In 2019, 305 million units, and in 2020, 283 million units of pharmaceuticals were produced. 37 percent of the production was carried out for the world's leading pharmaceutical companies.

Inspected and approved by the authorities and companies of the leading countries in drug production in Europe and the world, Esenyurt Production Complex was audited and rated successful by 29 health authorities and clients in 2019 and 2020.

[p.87](#) You can find the audits conducted here.

[p.87](#) You can access the Esenyurt Production Complex virtual tour video here.

AbdiBio Biotech Pharmaceutical Production Facility

ISTANBUL / TURKEY

Abdi İbrahim has also taken an important step to produce biotechnological pharmaceuticals, the demand for which is almost entirely imported in Turkey, and established AbdiBio, the largest biotechnological pharmaceutical production facility in our country, with an investment of 100 million dollars. In the facility, which encompasses more than 13,500 square meters of indoors area and became operational in 2018, all the production processes are implemented, from the cell bank to the final product.

AbdiBio has an annual production capacity of eleven million vials, nine million syringes, twenty-two million cartridges and one million lyophilized. Biotechnological drugs to be produced for blood diseases, gastroenterological, dermatological and immunological diseases, as well as diseases such as cancer, diabetes and rheumatism that cannot be treated with pharmaceuticals produced by chemical methods, will become available in Turkey while also being exported, making Turkey a global player in the biotechnology market.

In 2020, the Bioanalytical laboratory investment within AbdiBio, in which the analytical characterization and analysis of protein and protein-derived molecules will be carried out, was completed. Other investments, the Process Development Laboratory and the mAb production area will enter operation in 2021 and 2023 respectively.



Biotechnology, which we see as the future of the pharmaceutical industry, is one of the most crucial areas of our 2025 strategic growth plan. The technology and production power we get from AbdiBio is our biggest advantage on this path.



Ramazan Karaduman
AbdiBio R&D and Projects Director

Abdi İbrahim R&D Center


ISTANBUL / TURKEY

Having been nourished by a strong R&D culture since the day it was founded, Abdi İbrahim established Turkey's first and largest accredited pharmaceutical R&D Center in 2008 with an investment of 40 million dollars, covering an area of 13,600 square meters. Providing high-tech services with the latest formulation and analytical method development laboratories, the Center has the ability and infrastructure to develop drugs with inhalation technology and nanotechnological methods that can meet the changing and developing needs of the national and international pharmaceutical industry.

The R&D Center focuses on developing innovative products, achieving high success rates in bioequivalence studies, accelerating signature product development processes, preparing Common Technical Document (CTD) files for Turkey, Europe and other regions, and developing value-added products. It also carries out know-how transfer through joint projects realized with scientific institutions at home and abroad.

Abdi İbrahim, which aims to maintain its leadership in the Turkish pharmaceutical industry by allocating resources to R&D, has experienced a very productive 2020 in terms of academy-industry collaborations through its development projects, process improvement and alternative resource projects.

| GRI | 203-1 | 203-2 |



We are planning to offer our wound dressing to patients for the first time with this formulation, in 2021. It is an environmentally friendly and easy-to-use product that meets medical device requirements, is effective and reliable, provides for speedy recovery and allows for the healing process to be monitored thanks to its transparency. Our product, which is a unique formulation combination of natural components of the skin, resveratrol-loaded hyaluronic acid, DPPC microparticles and a three-dimensional collagen-laminin dermal matrix, has unique content that will revolutionize the treatment of chronic wounds. We have already patented our wound dressing product, which is a local invention and a product of academy-industry cooperation, in 41 countries.



Udaya Dude
Abdi İbrahim R&D Director

Intellectual and Industrial Property Rights

Having competency at international standards in pharmaceutical production technologies, Abdi İbrahim's Turkish, European and international patent applications reached 193 as of the end of 2020, while the number of registered patents reached 26 in Turkey and 9 in Europe.

Abdi İbrahim had registered four utility models and four designs as of the end of 2020, and is among the leaders of the national pharmaceutical industry with two patent applications covered by intellectual property rights in 2020 and two patents approved by the European Patent Office.

A local invention from Abdi İbrahim: Wound dressing

Developed by Abdi İbrahim in collaboration with Ege University, the wound dressing facilitating tissue repair with its unique properties, offers effective treatment. The wound dressing, which is a bioactive product manufactured using high technology to be used in the treatment of chronic wounds, has obtained patents in at total of 41 countries, including Turkey, the USA, Japan, Russia, China, Australia and South Africa and 35 in Europe. The dressing that accelerates wound healing with its spongy and reticulated structure consisting of human skin components, creates a biodegradable scaffold when placed on the wound, to ensure healthy tissue formation. It has a unique content as it is the first and only product that contains hyaluronic acid, DPPC and resveratrol microparticles together in the matrix structure of collagen, gelatin and laminin. The innovative treatment product Abdi İbrahim offers to the world from Turkey, will be available for use on patients in 2021, following eight years of R&D studies.

| GRI | 203-1 | 203-2 |



Abdi İbrahim Logistics Center

ISTANBUL / TURKEY

In 2010, Abdi İbrahim launched the Abdi İbrahim Logistics Center, an investment of 35 million dollars which has an indoor area of 22,600 square meters and a total pallet storage capacity of 14,500 EUR-pallets. The Center represents the state-of-the-art technology in logistics, where all operations including material handling are electronically managed with zero manual intervention. In the Center, temperature and humidity values are kept under control 24/7 with the building monitoring system, and an average of 1,100 pallets are moved per day.



Hormone Production Facility

ISTANBUL / TURKEY

The Hormone Production Facility, which covers an area of 620 square meters, started production in 2018. The facility, which has the capacity to meet a significant demand in Turkey, is the first hormone production facility to be approved by the European Union authority.

In 2019, approximately five thousand EUR-pallets of pharmaceuticals were exported to 53 countries from the Logistics Center, and more than 28 thousand EUR-pallets were shipped to 26 companies as part of contract manufacturing. Throughout the year, approximately 69 thousand pallets were handled in the finished goods warehouse. In 2020, approximately 5 thousand EUR-pallets of pharmaceuticals were exported to 52 countries, and more than 31 thousand EUR-pallets were shipped to 24 companies as part of contract manufacturing. During the year, approximately 63 thousand EUR-pallets were sent to the finished goods warehouse.

Abdi İbrahim Global Pharm (AIGP) R&D Center and Production Facility

ALMATY / KAZAKHSTAN

Abdi İbrahim established Abdi İbrahim Global Pharm (AIGP) company in 2012 by purchasing 60 percent of Global Pharm shares, one of the leading pharmaceutical manufacturers in Kazakhstan. AIGP, which was established over 12 thousand square meters of indoor area and started its operations in 2015 with an annual production capacity of 24 million units, is Abdi İbrahim's first production facility outside Turkey.

AIGP, which is the most modern GMP production facility in Kazakhstan, has a wide portfolio of approximately 100 products, mainly targeting diabetes or antiviral, used in the treatment of cardiovascular diseases and those of the central nervous system. Among the main objectives of the AIGP is to contribute to the pharmaceutical industry of Kazakhstan by offering innovative pharmaceuticals, and to become a leader in pharmaceutical exports to the Commonwealth of Independent States (CIS) countries through the establishment of multidimensional marketing.



| GRI | 203-1 | 203-2 |



Abdi İbrahim Remede Pharma (AIRP) R&D Center and Production Facility

ALGIERS / ALGERIA

Abdi İbrahim, which opened its first representative office abroad in Algeria in 1999, joined forces with Remede Pharma in 2014 to establish Abdi İbrahim Remede Pharma (AIRP), and made the most modern factory investment of the country's pharmaceutical industry. Covering an area of 5 thousand 678 square meters and having started its operations in 2017 with an annual production capacity of 51 million units, the GMP certified AIRP has a product portfolio comprising: cancer and diabetes pharmaceuticals, antipsychotics, antidepressants, urology, iron and respiratory products.

Investments

Abdi İbrahim, which has been prominent with its investor identity since the day it was founded, avoided any delay in its investments in 2019 and 2020, even when the world was going through an extraordinary period.

Abdi İbrahim is an avid investor and always remains enthusiastic about the subject, no matter the circumstances, having invested 620 million dollars since 1990 in Turkey and abroad.

Abdi İbrahim sees investment as “production, employment and export”, and instead of postponing its investment plans during the years 2019 and 2020, years that covered an extraordinary period around the world, it has taken important steps both in Turkey and international markets.

Passionate and emboldened to reach its assertive growth targets, the Company’s 2019-2020 investments of note are as follows:


OM Pharma acquisition investment

Taking a historic step towards becoming a strong international player, Abdi İbrahim has acquired together with a Swiss joint venture group, OM Pharma, an 83-year pharma company of pharmaceutical industry leader Switzerland. Purchasing 28.5 percent of OM Pharma shares at 500 million Swiss francs (approximately TRY 4.2 billion), Abdi İbrahim has become the sole foreign partner in the group.

AbdiBio Product Development Laboratory

A Biotechnological Product Development Laboratory investment was realized within AbdiBio Biotechnological Pharmaceutical Production Facility. In this laboratory, which covers an area of 300 square meters, in addition to product development studies, products with small serial sizes can be manufactured. The laboratory, which is largely completed, will become operational in 2021.

Investment amount*
(Million USD)



* Including overseas and subsidiaries.



Sterile Ophthalmology and Sterile Inhalation Production Facilities

Sterile Ophthalmology and Sterile Inhalation Facilities have begun production in 2020. Established over an area covering 2,500 square meters, the facility has an annual production capacity of 600 million vials.

Sterile Injectable and Oncology Production Facility

The Sterile Injectable and Oncology Production Facility, established on an area covering 48 thousand square meters, will start production in 2022. The center, which will be the largest sterile production facility in Turkey, will manufacture products in different forms (conventional, sterile, semi-solid, oncological).



In 2019 and 2020, many equipment and revision investments took place in the production areas, quality control and R&D departments of Abdi İbrahim's production facilities in Istanbul, Kazakhstan and Algeria.



Marketing and Sales

Abdi İbrahim offers nearly 200 brands and more than 400 products to the service of humanity with Turkey's largest and most competent marketing-sales team.

Through the widest brand and product portfolio in the Turkish pharmaceutical industry, Abdi İbrahim serves human health with its products in almost every therapeutic area. Aiming to heal more and more people every year by creating other strong trademarks in its field as well as developing its existing products, Abdi İbrahim serves nearly half of the more than

155 thousand doctors working in Turkey, thanks to its strong field teams organized throughout the country, and engages with over 20 thousand pharmacies one-on-one. In its sales and marketing channels, the company adopts an effective and efficient approach that is compatible with the developing technology and changing industry conditions.



During the course of the COVID-19 pandemic, the pharmaceutical industry has been at the center of change and transformation. Our main goal in our new normal marketing approach has been to understand people's behaviors, living habits, health-related expectations and needs, and deliver the most appropriate products and services to people in the most effective way. We have achieved this by enhancing our digital competencies, our innovation power and sticking to our community service motivation. In light of this, we will continue to plan our marketing and communication activities, according to the priorities in our VISION 2025 strategic roadmap.



Dr. Oğuz Mülazımoğlu
Abdi İbrahim
Head of Prescription Products
Marketing and Sales Group

We continue our work of presenting the Turkish pharmaceutical industry's most extensive product portfolio all over Turkey with pride. It is a source of motivation for us to be able to serve our doctors and pharmacists almost every in our country as part of the strongest marketing-sales team in the sector. Furthermore, thanks to our promotional model that is compatible with technology and the dynamics of the sector, our marketing-sales activities are rendered much more efficient.



Hakan Özdayı
Abdi İbrahim
Ankara Hematology & Oncology
Regional Manager


International Markets

| GRI | 102-6 |

Continuing its operations in more than 60 countries with different business models, Abdi İbrahim is taking strategic steps towards becoming a strong international player.

Abdi İbrahim, which carries out all its operations outside Turkey with an International Markets team of approximately 600 people, adds to its strength in its countries of operation every year. With the aim of carrying its market leadership success in Turkey overseas, the Company is taking important steps towards licensing Abdi İbrahim products to foreign companies, establishing long-term cooperation, increasing foreign sales revenues from and the number of countries in which it operates.


The aim of Abdi İbrahim, which has expanded its cooperation in sales, marketing and production areas related to global signature products in the different geographies where it operates, is to further expand its existing operations in Kazakhstan and Algeria as part of its innovative product portfolio. In addition, it sees Germany, England, France, Italy, Spain, Switzerland, United Arab Emirates, Saudi Arabia and the Philippines as priority target countries with regards to portfolio and company acquisitions and joint venture partnerships.



Our aim is to increase our volume in the markets we are in, to recruit human resources to support our growth targets, and to contribute to the development of our employees. We have goals such as establishing a presence in new geographies of strategic priority with our own teams, establishing new local companies, and ranking among the top ten pharmaceutical companies in the countries in which we operate. For the short term, we are working with all our strength to establish our systems and processes, to shape our future portfolio and to lay the foundations of our future organizations in order to achieve the desired growth in the countries where we are present. For the medium and long term, we strive to be a significant, reputable and respected company in strategic countries and markets with our own team.



Köksal Ülgen
Abdi İbrahim Head of
International Markets Group



Licensed Product Distribution
By the end of 2020, the number of licensed products by Abdi İbrahim in international markets had risen to
1,230

443
Countries where Abdi İbrahim is present with its own organization

- Albania: 54
- Kazakhstan: 67
- Algeria: 46
- Azerbaijan: 75
- Georgia: 98
- Tunisia: 25
- Bosnia and Herzegovina: 36
- Iraq: 42

32
EU
Number of licenses on Abdi İbrahim's behalf

496
EU
Number of out-license licenses

15
Canada

124
Middle East and North Africa

- UAE: 14
- Qatar: 44
- Jordan: 15
- Lebanon: 18
- Morocco: 10
- GCC: 8
- Saudi Arabia: 15

69
Other countries


- Pakistan: 2
- Northern Iraq: 26
- Kosovo: 6
- Guatemala: 1
- Colombia: 6
- Dominican Republic: 1
- Australia: 2
- South Africa: 14
- Honduras: 1
- Hong Kong: 2
- Switzerland: 4
- Singapore: 4

51
CIS
Commonwealth of Independent States

- Uzbekistan: 11
- Belarus: 1
- Turkmenistan: 12
- Ukraine: 11
- Russia: 16

Procurement and Supply Chain

Working with approximately 5 thousand suppliers, Abdi İbrahim maintains its relations with each of its domestic and international business partners in the supply chain within the framework of ethical values such as honesty, fairness, openness and accuracy.



Abdi İbrahim makes purchases in three main areas: direct materials, indirect materials and investment areas. These purchases are planned in line with the company's long and short-term policies. The selection of suppliers and the development of business procedures are among the issues considered important by Abdi İbrahim in purchasing processes. Abdi İbrahim prefers working with companies that can be relied on for long-term and sustainable cooperation, and pays the utmost attention to the compliance of its suppliers with legal regulations and ethical rules in the field of occupational health and safety. The company also carries out activities to increase the capacity of its suppliers in the field of sustainability.

The Company, which uses the Labor Law No. 4857 as a reference point in the control and procedure processes, as well as the contracts concluded with the supplier companies, currently has approximately 5,000 suppliers through direct and indirect purchases. The annual number of orders reaches 30 thousand.

Abdi İbrahim conducts its procurement and supply activities within the framework of the following universal principles:

- › Quality
- › Economy
- › Security
- › Ethics
- › Protection of society and the environment

Rate of local suppliers

Abdi İbrahim has worked with approximately 1,233 suppliers in 2019 and 2020, with the ratio of local suppliers to all suppliers being 68 percent.



Ufuk Güler
Abdi İbrahim Supply Chain
and Procurement Director

Since pharmaceutical production is a high-end and regulated production, the application of new technologies to all purchasing procedures is necessary. Abdi İbrahim's strength and flexibility is due to it keeping track of new developments and investing in technology in all domains.




Rami Atikoğlu
BASF Türk General Manager,
Turkey-Azerbaijan Country
Group President

As BASF Türk, we have been supplying raw materials to Abdi İbrahim for more than 30 years. We are proud to support the activities of Abdi İbrahim, the leading pharmaceutical industry company of our country, with our accumulated global knowledge and local experience. We closely follow its investments in biotechnology and consumer health, and support the robust steps it has taken in the fight against COVID-19. We appreciate the R&D investments, employment opportunities, and the value given to female workforce by Abdi İbrahim, the healing force of Turkey, and we wish for our cooperation to continue for many years to come.

EMPLOYEES






Those who improve life with their passion and talent for healing

Adopting the philosophy of "people first" in its management policy, Abdi Ibrahim attaches great importance to the health, safety and happiness of its employees, and regards its transparent, participatory, sharing culture that values individual leadership, self-responsibility and team play as the driving force of the company's success.



Key Performance Indicators (KPI)

| GRI | 404-1 |

	To continuously support the development of employees hired as talents and prepare them for higher positions	Rate of internal promotions at manager level and higher →	61% 2019	50% 2020	Rate of rotation, as a significant development activity →	4.1% 2019	3.7% 2020			
	To increase employee competence through training programs	Average training time per employee →	31.05 hours 2019	40.1 hours 2020	OHS training time in production facilities →	6.62 hours 2019	4.30 hours 2020			
	Promoting women's employment and equal opportunities	Rate of women employed in Abdi İbrahim headquarters →	56% 2019	55% 2020	Rate of women employed in the R&D center →	64% 2019	62% 2020	Rate of women employed in the Leadership Team →	27% 2019	20% 2020
	Retaining employees with high potential and performance	Rate of loss in this target group, designated as the rate of unwanted loss →	3.9% 2019	3.8% 2020		Supporting participatory management	As of the end of 2020, 126 projects were implemented through AiDEA, which received 1,232 suggestions by employees . Employees sharing their suggestions have been awarded a total of TRY 93,940 .			

Human Resources Strategy

Believing that long-term vision and goals can only be achieved with the right team, Abdi İbrahim aims to contribute to the creation of a mentally and physically sound society and workforce with its deep-rooted culture and strong corporate structure.

Abdi İbrahim regards each of its employees as a talent, and designs processes to reveal their potential so as to create the opportunity and environment for them to continuously develop. The priorities of the Company's human resources strategy, which adopts the principles of reliability and transparency, are as follows:

- › To provide an enthusiastic working environment and atmosphere.
- › Excellence in talent management and backup.
- › To establish a performance culture associated with strategic priorities.
- › To develop the technical competencies and leadership skills required by the strategy.
- › To create the system and sustainable procedures required by the HR infrastructure.

Healing life requires us to initiate ambitious transformations not only with our products and services, but also with our company culture. We know that this is possible by trying new things and as we always say, by working with courage, passion and responsibility, and learning new things everyday. As the market leader, we continue to take robust and accurate steps and heal the life and the future during the pandemic period, where our business and development priorities learning agility, uncertainty management, normalization and embracement of change, planning and efficient resource use are more important than ever.



Hakan Onel
Abdi İbrahim Head of
People and Culture Group

Human Resources Practices

Abdi İbrahim, which is among the most preferred companies in the pharmaceutical industry, offers its employees a working environment at international standards and extensive social benefits.

Abdi İbrahim adopts and implements legal regulations, standards and contemporary management systems in the field of occupational health and safety, and follows technological changes and developments. Providing strong support to the Turkish economy with its active employment policies in line with its growth plans, the Company draws attention with its human resources experienced and specialized above the sector average and its high rate of employee loyalty.



Çiğdem Sayın
Abdi İbrahim Otsuka
Regional Manager

Abdi İbrahim is the best school in the industry. As you learn the job within the framework of the most accurate and ethical rules here, in the meantime you strengthen your accumulation with training that contributes to your personal development. As one of the female members of Abdi İbrahim, the fact that our company values women's employment, and provides a working environment where human rights are respected without any discrimination such as based on religion, language, race or gender, evokes confidence in us. I feel fortunate to be a part of this family.




Gender equality and diversity

Female employees have always been a significant source of strength throughout Abdi İbrahim's century spanning history. The contributions by female employees have been substantial in every undertaking of the company since its founding generation, and has made Abdi İbrahim a pioneering institution in the business world in ensuring gender equality.

As a signatory of the United Nations Global Compact (UNGC) and the Women's Empowerment Principles (WEPs), Abdi İbrahim attaches great importance to the employment of women and supporting them. It does not discriminate against race, language, religion, age or gender in human resources processes; and is committed to providing a fair, egalitarian working environment that respects human rights. Procedures, such as recruitment, assignment and promotion within the company, are carried out by considering the criteria of professional experience and expertise.

| GRI | 405-1 |

NUMBER OF EMPLOYEES



Supporting local employment

Abdi İbrahim has a field organization distributed all over Turkey, and supports local employment in the mass recruitment procedures it carries out for field sales positions. In promotion procedures, on the other hand, managerial potential is evaluated and a candidate from the local community is preferred among two employees with equal potential. As a result of this company policy, the rate of promotion from local people at the Senior Management level (Regional manager, product manager, director, etc.) has reached 70 percent.

Employer-employee relations

| GRI | 102-41 |

Abdi İbrahim does not have an organized union. The Company operates within the framework of respect for employee rights under existing legal regulations applicable to business life, and regularly audits its suppliers.

An app that supports participation: AİDEA

Abdi İbrahim attaches great importance to instilling a sense of volunteerism in its employees, and encourages them to create projects on their own initiative through the AİDEA Suggestion System it implements. In this context, AİDEA, where suggestions received since 2011 have been evaluated and implemented and with employees being rewarded in line with the commercial contribution they create, contributes to the sustainability goals of the company. As of the end of 2020, 126 projects were implemented through AİDEA, which received 1,232 suggestions by employees. Employees sharing their suggestions have been awarded a total of TRY 93,940.

For me, the 30 plus years I have spent with Abdi İbrahim means "family, stability and peace". The continuous leadership of Abdi İbrahim in the industry, its lofty goals, the good relations I have with my colleagues and my efforts being rewarded are factors that keep me happy and motivated. I am very happy to work in a family environment of love, respect and peace.



Zihni Tuncay Şengünlü
Abdi İbrahim Medical Sales
Representative



Talent management

Abdi İbrahim attaches great importance to talent management to provide a passionate working environment and atmosphere. Talent management implemented in the company consists of recruitment, orientation, performance management, competency evaluation, feedback and development planning processes.

Objectives of talent management

- › To create a strong perception of Abdi İbrahim in potential candidates.
- › Choosing the right person.
- › To ensure that the right person quickly adapts to the job and the culture.
- › Setting business goals, evaluating success, nurturing with feedback.
- › To develop the employee in line with strategic priorities.
- › To select, train and retain the leaders of the future.

Abdi İbrahim Academy

The content of Abdi İbrahim Academy, where development solutions are presented in order to support strategic priorities and create a common culture; consists of corporate academy programs, basic technical trainings, e-trainings, social learning and Alpedia institutional library. Employees can participate in development programs with in-class training and receive e-trainings through this system.

Faculties within the academy

- › Faculty of Promotion
- › Faculty of Medical Marketing
- › Faculty of Continuous Development
- › Faculty of Leadership
- › Welcome Those Healing Life

Elixir Program for Young Talent Development (İKSİR)

Abdi İbrahim launched the Elixir Program for Young Talent Development in 2017 to attract talented new graduates and train young people with high potential as long-term employees. Young people who join the Abdi İbrahim family after going through many challenging stages are brought into a structured development program for a period of six months. The program which attracted the greatest interest from young people received more than 5,000 applications in 2019. over three years, a total of 45 candidates were accepted onto the program.

CAREer Factory Program for Young Talent Development

Abdi İbrahim launched the CAREer Factory Young Talent Development Program in 2019 for new graduate talents who want to start their careers in an industry leader company, and join the development journey of future leaders. Following a development and orientation process that lasts six months, the program offers a structured production career to be assigned depending on the staffing needs in the Esenyurt Production Complex. Of the nine people accepted within the program in a year, three are still working in the company.

Product Management Trainee (PMT) Young Talent Program

Abdi İbrahim launched the Path For Marketing Trainee Program for Young Talent Development to attract new graduate young talents with career goals in marketing. Young people who join the Abdi İbrahim family after going through many challenging stages are brought into a structured development program for 12 months. Those who successfully complete the medical sales representative task go on to work at Abdi İbrahim Tower. Those who successfully complete the process are appointed to the position of assistant product manager. In 2019, the program received more than 7,000 applications, and a total of 63 people were accepted over five years.



Didem Özalp
PERYÖN Turkey People
Management Association
Academy Director

Aiming for sustainability in success, Abdi İbrahim's Human Resources invests in the employer brand in line with its goal of creating a passionate working environment and atmosphere, and aims to provide its employees with a branded and planned experience. All members of Abdi İbrahim whose job is "to heal", work throughout the year to improve their work, themselves and their results, and be productive members of society. One of Abdi İbrahim's stakeholders, PERYÖN Turkey Human Management Association named Abdi İbrahim as the winner of 2018 Grand Prize for Leadership in Human Value by evaluating it under the topics Strategic HR Management, Human Resources Management Leadership, Communication Management, Innovation and Innovation Culture Development, Effective Workforce Management, Satisfaction and Loyalty Management, Development and Transformation Management, Improvement of Processes, Development in Performance Indicators and Perception Results with the contribution of the international evaluation firm and jury members. As PERYÖN, we are pleased to be cooperating with Abdi İbrahim, which emphasizes NGO and volunteer work, and make this cooperation sustainable.

Occupational Health and Safety Practices

Regarding occupational health and safety, Abdi İbrahim attaches great importance to the internalization of OHS culture in addition to the necessary technical equipment, as well as healthy facilities and equipment, in all business processes.

At all its facilities, Abdi İbrahim considers compliance with legal, international regulations and customer requirements, consistent development and the creation of a safe working environment with the participation of employee representatives, as the basis of its Occupational Health and Safety Policy. In addition to having all the legal permits, the Company holds the ISO45001 Occupational Health and Safety Management System Certificate.

Abdi İbrahim does not use any business process that would expose employees to high-risk diseases, and the company's aim is to increase the awareness of employees in the field of occupational safety through training. Internal targets are set every year to reduce the accident rate, while strategic studies are carried out to increase safe situations and behaviors. Efforts will continue with the same care and diligence in the future to lower the number of incidents or lost days.

In order to make a global comparison of accident rates, the Occupational Safety and Health Administration (OSHA) incident calculation rate has been adopted since 2018.



| **GRI** | 403-1 | 403-2 | 403-3 | 403-4 |
| 403-5 | 403-6 | 403-7 | 403-9 |

 You can find Abdi İbrahim's social performance indicators [here](#).

Occupational Health and Safety Trainings*



Occupational Health and Safety Indicators



The provision of long-term social benefit is a fundamental duty

Abdi Ibrahim is focused on continuous improvement across all its activities, and views the people it works with, its business goals, the world and the society in which we live, through the same lens. The company's social endeavors are realized with sensitivity for a healthy and clean environment, which is indispensable for future generations.



Key Performance Indicators (KPI)



To carry out community health projects

There are ongoing projects and awareness studies on social media that form part of the **Campaign for the Rational Use of Pharmaceuticals**, which was launched in 2012 to combat the ignorant use of pharmaceuticals,

Abdi İbrahim Otsuka (AİO) broke new ground on October 10, World Mental Health Day, and launched the **"Don't Say That"** movement for the prevention of **"stigma"**. Many such projects are being carried out at the moment.



Pioneering studies on community health

In cooperation with the Federation of Schizophrenia Associations, Abdi İbrahim Otsuka carried out and published the results of a **"Survey on the Perception, Knowledge Level, Stigma and Discrimination Regarding Schizophrenia in Turkey,"** which is the first study on this subject to be conducted in the country.



To support aid projects undertaken by non-governmental organizations

In the **41st Istanbul Marathon**, Abdi İbrahim ran for the **Hope Foundation for Children with Cancer (KAÇUV)**. Among the corporate teams participating in the marathon as part of the campaign, Abdi İbrahim ranked first in the number of campaigning runners.

Between 2016 and 2019, Abdi İbrahim's corporate running team **raised TRY 154,000**.



To organize campaigns for social awareness days

Various projects have been implemented for events such as **World Epilepsy Day, World Autism Day, World Parkinson's Day, World Bipolar Day, World Alzheimer Day, Breast Cancer Awareness Month, World Cancer Day**.



Organize assistance projects

Various assistance projects have been implemented for students, **patients in need, and stray animals**.

Social Investment Studies

In line with its plan for healing the future, Abdi İbrahim considers its long-term and result-oriented work aimed at providing social benefit as an integral part of its essential duty.

Focusing on shaping the future with the power of influence brought about by its well established and innovative structure, Abdi İbrahim realizes projects that intersect with its corporate values, touching all segments of society and creating social benefits that are in line with its plans to heal the future. With employees also taking part, it takes care to ensure that every step it takes in this context is applicable, sustainable, measurable, transparent and accountable on a global scale.

Abdi İbrahim will launch a new social investment program in 2021 in line with its corporate reputation and perception research studies, and the social benefit analyses it has carried out. The four main areas of focus within this program, which will have a long-term outlook, and forms one of the most important parts of the company's sustainability strategy, are as follows: "Health and Sports", "Social Innovation", "Raising Scientific Awareness in Youth" and "Volunteering Projects for Social Needs".

Areas of focus in the community investment program

HEALTH AND SPORTS

Raising awareness, health literacy, delivery of health services and pharmaceuticals to groups in need

SCIENCE

Promoting science for children, young people and women, contributing to the training of scientists, supporting scientists who make a difference

INNOVATION

Contributing to the sector by supporting social innovation in health

VOLUNTEERING

Creating both corporate belonging and social benefit with various projects by forming a systematic volunteering structure

Abdi İbrahim Foundation

Abdi İbrahim will also launch the Abdi İbrahim Foundation in 2021. Abdi İbrahim Foundation, founded by Nesrin Barut Esirtgen, Nezih Barut, Ahmet Cenani Esirtgen, İbrahim Barut and Abdi İbrahim Pharmaceuticals, aims to increase interest in science, sports and education of our young people, who are the future of our country, and to support them as they grow into well-equipped and skilled individuals, who uphold modern, universal values and the foundational principles of the Republic. The Foundation will operate in the field of sports, education, health and care services.

As a company that attaches great importance to the right of the individual to health, education, equality of opportunity and living in a healthy environment, we cooperate with public, private sector and non-governmental organizations in Turkey and in all geographies where we operate, and we pay close attention to the social and environmental impacts of our work. We focus on healing in every field and attach great importance to projects that provide social benefits. Through the preliminary studies we have conducted, we have determined our community investment programs and gathered them into four distinct groups. The year 2021 will mark the beginning of a period in which Abdi İbrahim will be remembered for its projects generating social benefits.



Buket Koral Gönüllü
Abdi İbrahim Corporate
Communications Manager

As Mikado, we are happy to work with an institution like Abdi İbrahim, which has a broad vision and invests in innovation. Together we have developed the Social Innovation Program in Health. The aim of this program is to encourage social entrepreneurship in the field of health and to support existing entrepreneurs. While Abdi İbrahim's flexible and courageous approach shapes the projects, it not only creates opportunities for cooperating stakeholders like us, it also enables the creation of high impact social investment programs.



Serra Titiz
Mikado Consulting Founder
and Manager



You can look at Abdi İbrahim's social benefit activities and projects implemented before 2019 in the Sustainability Reports.

2019 Projects



Ayakları DONMASın with Patyca!

Abdi İbrahim Achilles team gave 800 pairs of boots and coats to 600 students from 12 schools in Kars, Hakkari, Bitlis, Diyarbakır, Şanlıurfa, Mardin and Kahramanmaraş with the project "Ayakları DONMASın" (Keep their feet warm) under neuropathic pain medicine sponsorship.

"Women improve Life Through Healing" event

Abdi İbrahim Herakles team organized a public information meeting called "Women improve Life Through Healing" with İstanbul Çatalca Municipality on April 30, 2019. The speakers at the meeting were Gastroenterologist Prof. Dr. Filiz Akyüz, Gastroenterologist Assoc. Dr. Züleyha Akkan Çetinkaya and Gastroenterologist Specialist. Dr. Ayça Değirmenci and discussions included healthy eating, stress and digestive system diseases and the health benefits of physical activity.



Press conference on World Epilepsy Day

The Turkish Association for Combating Epilepsy held a press conference in İstanbul with the support of Abdi İbrahim as part of the 26 March World Epilepsy Day. At the meeting organized to raise awareness among the public, the results of the "Epilepsy Patient and Relatives Insight Research", the most detailed study ever conducted on epilepsy patients, were announced. In addition, the "Legal Rights of Individuals Living with Epilepsy in 100 Questions" was introduced, a book prepared for the first time in Turkey to offer guidance on the legal problems patients face in their business and social lives.

April 2 World Autism Awareness Day

Abdi İbrahim Otsuka team dedicated April 2, World Autism Awareness Day, to families of children with autism. The otizmailem.com website was introduced to patients as an accurate source of information where ambulatory care is limited, as part of efforts carried out by child psychiatrists on the field. The autism patient story video "Bulut's Story" was shared on the company's social media accounts as an important step in raising autism awareness among the public, reaching 180,000 people. During this special day, presentations and meetings were also held in many cities to raise awareness.



A new campaign from "Let Our Name be Good"

Abdi İbrahim Otsuka team gave musical instruments to community mental health centers in İstanbul for use by patients during their rehabilitation, as part of the campaign they organized through the "Let Our Name be Good" project. Musical instruments such as violins, flutes and organs donated by Abdi İbrahim members as part of the campaign are now being used in the rehabilitation of patients.

We Are Together in TRSM

Abdi İbrahim Otsuka conducts works in many fields at Community Mental Health Centers with the brand "We are Together in TRSM". In January, a t-shirt painting activity was organized under the direction of a TRSM physician in Ankara Sincan TRSM to support the treatment of patients with occupational therapy. The "Monthly Occupational T-shirt Painting" video on the www.gormezdengelmeyelim.com website and the objects made with materials supplied by Abdi İbrahim Otsuka were met with great appreciation.



World Alzheimer's Day events

Abdi İbrahim Hercules team became the voice of Alzheimer's patients on September 21, on the occasion of World Alzheimer's Day. Collaborating with the Alzheimer's Association of Turkey, the team carried out activities for patients and their relatives all over Turkey with the concept of "Hear the Voice of Alzheimer's". The activities, which began with a press conference organized by the Alzheimer's Association of Turkey on September 18, continued with municipality-supported meetings and social media posts. The events included two million people being reached through press and social media campaigns.

Alzheimer's voice: Gaziemir public meeting

Abdi İbrahim Hercules/Alzheimer team organized one session of the awareness and information meetings for patients and their relatives in İzmir Gaziemir Municipality. A total of 125 relatives of patients attended the meeting, which was led by Prof. Dr. Görsev Yener of Dokuz Eylül University Faculty of Medicine and Assoc. Dr. Özge Küsbeci of İzmir Bozyaka Training and Research Hospital.



Abdi İbrahim goes purple for epilepsy

Epilepsy, which is a group of neurological disorders defined by seizures, is found in 50 million people all over the world. Turkey accounts for about 700,000 of them. In order to draw attention to this disease and raise awareness, between March 26 and April 1, 2019, Abdi İbrahim Tower was illuminated in purple lights, the color used to symbolize epilepsy.

Abdi İbrahim Tower illuminated in orange

Abdi İbrahim Tower was bathed in orange lights, the color of the Alzheimer's Association of Turkey, on 20-21 September 2019 to draw attention to Alzheimer's disease. Inside the building, on September 20, music was broadcasted throughout the day for the same purpose.

World Bipolar Day events

As part of World Bipolar Day on March 30, various activities were held at Şişli French Lape Hospital with the unconditional support of Abdi İbrahim and with the participation of patients and their relatives. The themes of prevention of stigma and creativity were emphasized at the events.



Aid campaign for stray animals

The Girls Power group, comprising Abdi İbrahim employees, organized an aid campaign for stray animals on July 19, 2019 as part of the Quality Development Program. The team has collected a significant amount of donations in a short time.



Time for action

Abdi İbrahim Parkinson team produced and shared an awareness video in cooperation with the Parkinson's Disease Association of Turkey, on April 11, World Parkinson's Day, in order to raise awareness and ensure that symptomatic and undiagnosed patients consult a doctor. In one week on social media, the video was watched 2.5 million times and had 700 thousand unique visitors.



Tournament for Breast Cancer Awareness

In October, the month of breast cancer awareness and awareness, Abdi İbrahim organized awareness events on social media and within the company. As part of these events, Senior Product Manager Şafak Yılmaz represented Abdi İbrahim at the Tournament for Breast Cancer Awareness held at Ankara Golf Club on October 20, 2019.

Turkey's first schizophrenia perception research by Abdi İbrahim Otsuka

Federation of Schizophrenia Associations and Abdi İbrahim Otsuka announced the results of a "Survey on the Perception, Knowledge Level, Stigma and Discrimination Regarding Schizophrenia in Turkey," which is the first study to be conducted in the country in this field, in the press conference held on the occasion of World Mental Health Day. The research reveals how schizophrenia is perceived in our society, how much is known about schizophrenia, and the level of stigma and discrimination related to schizophrenia; and it is to guide the agenda for combating stigma and discrimination related to schizophrenia, which will be implemented in the future, to raise awareness of the society about schizophrenia and to enable people to empathize with patients.

The biggest obstacle to the treatment of mental illnesses is the tendency for stigma and discrimination in society. Therefore, in order to achieve success in the early diagnosis and treatment of mental illnesses, it is necessary to reduce both stigma and discrimination. In the "Survey on the Perception, Knowledge Level, Stigma and Discrimination Regarding Schizophrenia in Turkey" we have conducted in cooperation with Abdi İbrahim Otsuka, we have exposed the perception of schizophrenia in the society, our level of knowledge in this area and some very important data on stigmatization. We will continue to fight stigma and discrimination with everything we have.



Assoc. Dr. Haldun Soygur
President of the Federation of Schizophrenia Associations



Abdi İbrahim members became hope for children in Istanbul Marathon

In the 41st Istanbul Marathon, organized on November 3, Abdi İbrahim ran for the Hope Foundation for Children with Cancer (KAÇUV). Among the corporate teams participating in the marathon, Abdi İbrahim ranked first in the number of campaigning runners, fifth and tenth in donors reached and overall donations, respectively. Abdi İbrahim's corporate running team, which supports the Umudum (My Hope) Education Project, the scholarship program of KAÇUV for children with cancer to continue their education from where they left off, collected a total donation of TRY 154,000 between 2016-2019.


A new undergraduate course from Abdi İbrahim

Maintaining support for university students, Abdi İbrahim's people came together over a period of 24 weeks with Istanbul University Faculty of Pharmacy 3rd year students in the Career and Development Curriculum. As part of the program, students were supported in preparing for business life and developing behavioral competencies before graduating, in the courses where subjects not included by the curriculum such as effective communication, relationship management and leadership were handled.

2020 Projects


Commendable contribution in the fight against COVID-19

Abdi İbrahim has moved proactively to mobilize against the pandemic, implementing the Campaign to Contribute towards the Fight Against COVID-19. It has manufactured and donated to the Ministry of Health the medicine among its products that has proven to be effective in the treatment of COVID-19 and became part of the treatment protocol.

 [Information about the campaign can be found here.](#)

Support from Abdi İbrahim to TÜSİAD's New Climate Regime Report

Abdi İbrahim, which is continuing its sustainability efforts for a more livable world at full speed, has been involved as a business partner in the "New Climate Regime Report from the Lens of Economic Indicators" led by TÜSİAD. The report, which was prepared with the support of Abdi İbrahim, and as a part of TÜSİAD Energy and Environment Roundtable activities, discusses the impact of the anticipated new climate regime on the national industry with economic models.



Do Not Ignore Exhibition at Sabiha Gökçen Airport

Abdi İbrahim Otsuka's "Do Not Ignore - Schizophrenia from Prehistory to the Present" exhibition, which deals with the transformation process of schizophrenia from past to present, drew interest from Istanbul residents for the fifth time. Do Not Ignore, exhibited at Sabiha Gökçen Airport Domestic Departures Terminal between January 22 and February 8, will be exhibited in different parts of Turkey every year to raise awareness about schizophrenia and hold in check the stigmatization of patients.



Blood and stem cell donation to the Red Crescent

Under the cooperation of Abdi İbrahim with the Turkish Red Crescent, employees at Abdi İbrahim Tower and Esenyurt Production Complex donated more than 80 units of blood and stem cells on January 30.



Mavi Köy (Blue Village) Center for Life with Diabetes opened

Established by the Turkey Diabetes Foundation for Type 1 diabetes, for children and young people dependent on insulin, the "Mavi Köy Center for Life with Diabetes" the largest diabetes education complex of its kind in Europe, was opened in Şile, Istanbul on August 29. At the opening, a plaque expressing thanks was presented to Abdi İbrahim, who supported the center by donating.

The Turkey Diabetes Foundation established the country's first diabetes life center, which had been in the construction phase since 2012, to teach children and young people with diabetes how to live with the condition and how to deal with the problems beyond the hospital environment. The health team, comprising specialist physicians, nutritionists, nurses and psychologists will be able to counsel 4,000 patients a year.

AİO team ran for schizophrenia awareness

A team of 30 people, comprising Abdi İbrahim Otsuka employees and Akdeniz University Faculty of Medicine Department of Psychiatry Gündüz Hospital students and employees, ran to raise awareness for schizophrenia in the 14th Runatolia Marathon held in Antalya on March 1.

Two mobile apps for Alzheimer's and Parkinson's patients

Breaking new ground once again during the fight against COVID-19, Abdi İbrahim developed two mobile applications aimed at facilitating the lives of Alzheimer's and Parkinson's patients, and their relatives who are unable to leave their homes during this period. A first in its field, the application "My Parkinson Helper" facilitates the practical monitoring and analysis of the daily and weekly state of patients, while allowing patients or their relatives to periodically answer the questions in the application and share them with their physicians, without restricting their daily lives.

In the "Alzheimer's Voice" application, which includes content prepared by experts, which is very important for patients with Alzheimer's disease, such as safety, personal care, nutrition, sleep patterns and risk factors, questions people may have about the disease are answered using videos. Questions that are not readily available in the application are directed to experts, and the answers received are uploaded to the application in the form of short videos, contributing towards meeting the needs of patients.

These two applications are very convenient for patients' relatives in terms of monitoring the course of the disease and patient care, in a country where there are approximately 150,000 people with Parkinson's disease and 600,000 people with Alzheimer's.



As the Alzheimer's Association of Turkey, we have provided support to the "Alzheimer's Voice" application, unconditionally supported by Abdi İbrahim, and created it with the aim of raising awareness in society about the prevention of Alzheimer's and other dementia diseases, the care of patients, and improving the quality of life for people with these diseases and their families. We have moved our work in this field onto an online platform during the pandemic process. The COVID-19 pandemic has unfortunately had a negative impact on the lives of Alzheimer's and dementia patients, as well as their relatives. We have carried out information and support activities to stand with patients and their relatives who faced great difficulties during the pandemic period. As part of our work for the "Hear the Voice of Alzheimer's" concept, we organized activities all over Turkey for patients and their relatives, reaching millions. We will continue and expand our services to patients and their relatives.



Prof. Dr. Haşmet Hanağası
President of the Alzheimer's Association of Turkey



Abdi İbrahim turned off its lights to illuminate the future

Abdi İbrahim turned off its lights on Saturday, March 28, between 20.30 and 21.30 in solidarity with the Earth Hour, an event that is annually observed by nearly 150 countries to draw attention to the climate crisis and loss of nature.

Abdi İbrahim stands by thalassemia patients in the pandemic

During the COVID-19 pandemic, children with thalassemia have been exposed to the risk of discontinuation in their treatment, and on August 20, Abdi İbrahim brought those children and their families together with physicians on an online platform. For the first time in Turkey, a digital platform was used for an awareness raising meeting, an event that attracted much attention. At the meeting, nearly 50 participants, patients and their families were given the opportunity to take advantage of the information provided by hematologists by asking them questions, and taking part in various activities.



Don't Say That!

As the force behind many significant and remarkable projects, Abdi İbrahim Otsuka (AİO) broke new ground on October 10, World Mental Health Day, and launched the "Don't Say That" movement for the prevention of "stigma". This movement, which drew attention to the negative impact of off-hand remarks such as *"are you schizophrenic or what"* or *"would you look at the bipolar here"* on people with mental health disorders, had more than five million views through social media interactions.

With the support of the Federation of Schizophrenia Associations, the Bipolar Life Association, the Turkish Neuropsychiatry Association and the Turkish Child and Adolescent Psychiatry Association, AİO will continue working actively to spread this movement to all parts of society and even transform it into a global movement.



You can access the movie of the "Don't Say That" movement [here](#).



A meaningful campaign from Izmir Region's employees

Abdi İbrahim İzmir Region employees launch a meaningful campaign. The team donated the blue plastic caps it has collected to the Turkish Paraplegia Association (TOFD).



Izmir earthquake aid

Following the earthquake in İzmir on October 30, 2020, Abdi İbrahim sent a truck to the city containing OTC products and materials to meet the needs of the victims of the quake.



Don't leave Hepatitis B diagnoses to chance!

Abdi İbrahim Hepatology team, by saying *"Do Not Leave Your Health to Chance"*, supported the activity *"We are Looking for the Missing Millions"* organized by the World Health Organization on July 28 to draw attention to viral hepatitis. During the week-long awareness activities, 2.7 million people were reached with six million views.



You can access the awareness film [here](#).

World Cancer Day awareness events

Abdi İbrahim Oncology team held awareness activities together with the Turkish Oncology Association, the Turkish Association for Cancer Research and Control and the Hope Foundation for Children with Cancer (KAÇUV) on February 4, World Cancer Day. The oncology team came together with the Turkish Oncology Association at a cancer awareness event held with the Marmara Forum, at which physicians and the media were also present.

On February 4, awareness posters prepared with the support of the Turkish Association for Cancer Research and Control were shared with the employees at Abdi İbrahim Tower. KAÇUV also visited Abdi İbrahim Tower and gave information about its activities and goals.



Gifts to make students happy


Organizing a social responsibility campaign for students in need of coats on cold winter days, Abdi İbrahim members gave 270 coats to children in Bingöl and Hakkari. Students and teachers shared photos and videos and showed their appreciation and love to the people of Abdi İbrahim.



Philanthropy

At every activity period, Abdi İbrahim allocates important resources to donations and aid for non-profit organizations in its investment and budget plans, and it has continued donations and aid in 2019 and 2020.

Donations and Aid
(Million TRY)



Help for student needs



"Good is Our Name" campaign



Aid campaign for stray animals



Support for the education of children with cancer at the Istanbul Marathon



Campaign to Contribute to the Fight Against COVID-19



Blood and stem cell donation to the Red Crescent



Donation to the Mavi Köy Center for Life with Diabetes



Donation to the Turkish Paraplegia Association



Izmir earthquake aid



Help for student needs

ENVIRONMENT

Abdi İbrahim aims to be carbon neutral by 2030

Aware of the fact that human health depends on the well-being of our planet, Abdi İbrahim carries out all its business procedures with the aim of minimizing its ecological footprint, while also aiming to lead the low-carbon transformation and sustainability of the Turkish pharmaceutical industry, and takes important steps in this context.



Key Performance Indicators (KPI)



To implement projects that contribute to environmental sustainability

Abdi Ibrahim

becomes the first Turkish pharma company to transition to **100 percent renewable energy.**



To decrease energy production through efficiency-oriented projects

Electricity saved through the substitution of tablet filter presses in machinery →

↓ **144** kwh
2019

↓ **26** kwh
2020



To decrease water consumption through effective recovery methods

Water saved through the projects implemented →

↓ **117** m³
2019

↓ **274** m³
2020



Decrease waste

Plastic saved through the thinning of transparent nylon bags by **12%** and blue gusset bags by **21.6%** →

↓ **4,500** kg
2020

Decrease in chemical consumption by substituting tablet filter presses in machinery →

↓ **54** kg
2019 (11 machines)

↓ **10** kg
2020 (2 machines)



Reduction in paper consumption

Paper saved through the projects implemented →

↓ **5,022** kg
2019

↓ **2,101** kg
2020

Preventing the **logging of 119 trees.**

Environmental Sustainability Strategy

By continuously maintaining its systematic work in the field of environmental sustainability, Abdi İbrahim contributes to green transformation through the implementation of a significant number of environmental protection investments and environmental impact mitigation projects.



Abdi İbrahim shapes its environmental strategy in line with the European Green Deal (The European Green Deal) and the UN's 17 Sustainable Development Goals (SDGs), as well as the materiality analysis and Organizational Life Cycle Analysis (O-LCA) carried out within the company. As the basis of its environmental policy, in all its activities the company takes into consideration the protection of the environment, continuous improvement, the effective use of natural resources, full compliance with the law and the prevention of pollution, the reduction and separation of wastes generated during its activities at source, recycling and disposal by the most appropriate methods.

Environmental targets

- › To become “carbon neutral Abdi İbrahim” by 2030.
- › To take steps in the reduction of carbon emissions across the entire value chain, as part of the Organizational Life Cycle Analysis (O-LCA).
- › To ensure the efficient use of all natural resources, especially water.
- › To promote the use of packaging materials that are less harmful to the environment, instead of packaging that contains plastic.
- › To take significant steps in waste management.
- › To organize training activities with the aim of raising environmental protection awareness, for employees, all third party companies and relevant parties.
- › To use the appropriate technology to control and minimize potential impacts on the environment.
- › To follow and comply with legal, international legislation and customer requirements in order to prevent environmental pollution, and to continuously improve environmental performance.
- › To continue taking steps to protect biodiversity.
- › To become one of the environmental sustainability leaders.

As part of our goal to bring our carbon footprint to zero by 2030, we are looking for sustainable, effective and innovative solutions at every level, such as the use of electric vehicles and trucks in the logistics department, the reduction of packaging waste, and collaborating with start-ups to develop new forms of packaging that have a lower impact on the environment. We continue to take important strides in the field of sustainability and heal the future, by closely following international standards through our membership of organizations such as CDP, SBTi, Turkey Circular Economy Platform, Turkey Materials Marketplace, and the Business Plastics Initiative.



Megi Erpardo
Abdi İbrahim
Public Affairs Manager

Environmental Group activities

Abdi İbrahim has an Environmental Group comprising seven people, including various departmental managers. The Group, headed by the Environmental Management Representative, monitors the performance of the Environmental Management System and makes the necessary updates through monthly meetings.


The activities carried out by the Environmental Group are as follows:

- › Field inspections,
- › Corrective and preventive actions,
- › Environmental legislation, regulations and legal compliance assessment,
- › Environmental aspect assessments,
- › Evaluation of environmental risks and opportunities,
- › Environmental management programs and objectives,
- › Evaluation of environmental proposals and projects,
- › Selection of environmental personnel of the month.

Abdi İbrahim has obtained effective results from its environmental impact control, target identification and program development works within the framework of Environmental Aspect Assessment Procedure and has a total of 51 environment aspect analyses regarding R&D, production and storage activities, third party company activities and buildings. In addition, environmental impacts are periodically monitored in terms of waste management, monitoring and measurement and emergency procedures. The Environment Group draws up programs to combat the identified problems and risks, and then focuses on the identified targets.

Environmental training

By focusing on carrying its environmental standards further as part of the principle of continuous improvement, Abdi İbrahim regularly maintains training programs covering standard facility practices, procedures, waste management, recycling, conscious consumption and issues to be considered in the home. An average of two hours of Environmental Management System awareness training is given annually during Environmental Management System training sessions, which are held with the participation of third-party companies and intern stakeholders. Attaching great importance to the topicality of environmental training and stakeholder participation, Abdi İbrahim encourages employees through its Environmental Person of the Month and Voluntary Environmental Education Project implementations.



Environmental Impact Mitigation Studies

Abdi İbrahim takes environmental impact into consideration in all its business processes from purchase to market launch, and implements effective policies on recycling and resource management.

Effective resource management

In accordance with the Waste Management Procedure, Abdi İbrahim separates all wastes generated during its operations at source. At the same time, it fulfills its obligations regarding product packaging that enters the market as detailed by the Packaging Waste Control Regulation of the Environmental Legislation. The Company, which has been collaborating since 2005 with the authorized organization ÇEVKO (Environmental Protection and Packaging Waste Recovery Foundation), works with companies licensed by the Ministry of Environment and Urbanization for the recycling and disposal of wastes.

Abdi İbrahim, which has a zero waste target as part of its circular economy efforts, will implement noteworthy projects such as the use of recycled paper for package inserts and boxes, Pet and R-Pet blisters, and the waste pharmaceutical project.



Waste from the Abdi İbrahim Esenyurt Production Complex is disposed of in accordance with the regulations. Waste water is treated biologically using MBR technology and the performance of the facility is constantly monitored.

Fatma Yalçın
Abdi İbrahim Environment,
Health and Safety Manager



Our annual targets and projects for water, natural gas and electricity consumption, which are a highly significant aspect of our environmental activities, are included in our company's Management Program. We reduce natural resource usage and waste rates, and achieve significant savings with the projects we carry out by also taking employee suggestions.

2019 and 2020 Savings

Thanks to the projects realized with employee suggestions, in 2019 and 2020 Abdi İbrahim achieved significant savings by reducing natural resource consumption and waste.

Paper saved



In 2019 and 2020, a total of **7,123 kg of paper** was saved and **the logging of 119 trees** was prevented.

By product package design **modifications** →

↓ **4,494** kg
2019

↓ **657** kg
2020

By Sotex test output **improvements** →

↓ **450** kg
2019

By ADR checklist electronic **management** →

↓ **78** kg
2019

By **not printing** documents approved via Qmex system →

↓ **665** kg
2020

By **reducing** the number of logbooks in product analysis →

↓ **240** kg
2020

By **improvement** of quality control report formats →

↓ **329** kg
2020

By **improvement** of stability report formats →

↓ **138** kg
2020

Execution of environmental management system processes from the EHS Pro system →

↓ **72** kg
2020

Water saved



A total of **391 m³ of water** was saved in 2019 and 2020.

By machinery tablet filter press **substitution** →

↓ **67** m³
2019 (11 machines)

↓ **12** m³
2020 (2 machines)

By increasing the charge for the manufacture of a given product to **decrease annual production runs** →

↓ **50** m³
2019

By WPU tank water level **reduction from 90% to 55%** →

↓ **262** m³
2020

Electricity savings



By machinery tablet filter press **substitution** →

↓ **144** kwh
2019 (11 machines)

↓ **26** kwh
2020 (2 machines)

Plastics savings



Through the **thinning of transparent nylon bags by 12% and blue gusset bags by 21.6%**

↓ **4,500** kg plastic
2020

Chemical savings



By machinery tablet filter press **substitution** →

↓ **54** kg
2019 (11 machines)

↓ **10** kg
2020 (2 machines)

Impact on Biodiversity

Abdi İbrahim does not operate in areas of high biodiversity and has 85 plant species and 146 large trees in the Esenyurt Production Complex, which has a grassland area of 22 thousand square meters.

At every stage, Abdi İbrahim keeps its environmental impact under control, from the purchasing process to the products reaching the market. By implementing sustainable waste management policies for the protection of the environment, its primary aims is to decrease waste at source, through source separation, recovery and disposal with appropriate methods, and through working with licensed companies.

At the Abdi İbrahim Esenyurt Production Complex, where natural gas is used for fuel, there is an online flue gas monitoring system. Dust emissions are kept under control thanks to special filters with 99.99 percent efficiency, and aqueous absorption systems used in ventilation systems.

In the Esenyurt Production Complex, membrane technology is used in the treatment of wastewater. Abdi İbrahim has also spearheaded the sector with its investment in the MBR (Membrane Bio Reactor) treatment method, which is an environmentally

friendly technology. The use of this technology has eliminated waste sludge generation from treatment sludge, and improved the quality of effluent by 70 percent to put it well below discharge thresholds.

The WRI (World Resources Institute) is acknowledged for the risk assessment of basin water in the area surrounding the facility where rainwater, water from the normal operation of water treatment systems, and backwashing water are used for garden irrigation. The water indicators on the WRI Aqueduct tool are reviewed, using the facility's location data.

Attaching great importance to the subject of plastics, Abdi İbrahim develops many projects for reducing the use of plastic, minimizing its footprint and even its substitution.

The Esenyurt Production Complex, which has a grass area of 22,000 square meters, hosts 85 species of plants and 146 large trees. Coniferous and deciduous species are pruned once a year in autumn, while other species are pruned two or three times a year.

| GRI | 304-1 | 304-4 |

Water Consumption

Water savings of 47,962 m³ achieved by Abdi İbrahim through the projects implemented between 2012 and 2020 corresponds to the monthly demand of 3,198 households or the yearly demand of 267 households.

Abdi İbrahim requires water of an appropriate quality for the pharmaceuticals it produces for human health and, as such, approaches the subject of water sustainability with great care. As it is of critical importance for the future of the world, it prioritizes its efforts to save water.

In the Esenyurt Production Complex, all necessary precautions are taken for the prudent use of water at every stage. Thanks to the care taken by employees and the automatic control systems, only sufficient underground water is extracted and passed through iSKI meters. In the facility, where both photocell and filter taps are used in the sinks, there are gun systems in the production area washing cabinets to ensure that water does not flow when it is not needed, and production equipment with automatic washing features.

As an important step in water sustainability on the way to healing the world and the future, Abdi İbrahim became the first signatory in the Turkish pharmaceutical industry of the CEO Water Mandate, an initiative of the United Nations Global Compact. In this way, through its commitments the company will continue to support the water protection policies that are simultaneously carried out all over the world.

| GRI | 306-1 |

Energy Consumption

In terms of energy efficiency, by saving 35 percent annually since 2000 Abdi İbrahim has saved a total of 1,460 tonnes of Oil Equivalent (TOE) energy.

Attaching great importance to the effective use of natural energy resources, Abdi İbrahim ensures continuous development in this field through its Energy Board. The Board, comprising directors, managers, engineers and technicians, has a sub-committee of 85 people, and holds general evaluation meetings at least twice a year. All technical personnel contribute to the sub-working groups according to their areas of expertise.

Abdi İbrahim, which aims to reduce its carbon footprint to zero by 2030, has taken an important step in this regard and as of January 1, 2020 has started to meet all the electricity needs of the Istanbul Esenyurt Production Complex from renewable sources, including wind and solar energy. In the year 2020, its energy consumption in the production complex was 44,209,606 kilowatt hours, coming down to an energy consumption equivalent to the yearly electricity consumption of 26,000 houses, met from renewable sources. With this practice, it has prevented carbon emissions equivalent to the annual use of 5,230 vehicles. Thus, the carbon footprint has been reduced by approximately 24,000 tons of CO₂ equivalent. Gradual transition to renewable energy use will be ensured throughout all processes.

| GRI | 302-1 | 302-3 | 302-4 | 302-5 |

Greenhouse Gas Emission

Abdi İbrahim, which closely monitors the efforts carried out on the global level to combat global warming, carries out systematic studies to reduce the CO₂ emissions resulting from its activities.

Abdi İbrahim utilizes the IPCC Methodology included in the "Greenhouse Gas Emissions Inventory Working Group 2006 Draft Report" published by the Ministry of Environment and Urbanization in April 2006, and is committed to becoming carbon neutral by 2030.

At the Esenyurt Production Complex, where no R22 gas –one of the gases detrimental to the ozone layer– has been released from 2014 to 2020, carbon emissions were calculated as 6,676 tons/year for 2019 and 8,855 for 2020.

The flue gas values emitted into the atmosphere are monitored 24 hours a day with online monitoring measurement devices installed on the steam boiler chimneys. The measured average values are given below:

› NO₂...60 mg/Nm³

› CO.....0 mg/Nm³

› SO₂....0 mg/Nm³

* CO, NO₂ values can be monitored online within Abdi İbrahim. Other emissions are evaluated in emission reports prepared within the framework of the spot measurements that are carried out every two years. Emission confirmation measurements were carried out for the Chemical Production Facility in 2019 and for the AbdiBio Biotechnological Production Facility in 2020.

ABDI İBRAHİM'S CARBON FOOTPRINT DISTRIBUTION	
Scope 1* 74%	Fixed burning
	Refrigerants
	Mobile burning
Scope 2 0%**	Electricity purchased
	Heating and cooling purchased
Scope 3 26%	01: Raw materials and services purchased
	02: Fixed assets
	03: Fuel and energy related activities
	04: Pre-production shipping and distribution
	05: Production waste
	06: Business trips
	07: Employee transportation
	08: Pre-production leased assets
	09: Post-production shipping and distribution
	10: Transactions of products sold
	11: Use of products sold
	12: Disposal of products sold
	13: Post-production leased assets
	14: Dealers
	15: Investments

Distribution, according to the scope of the corporate carbon footprint of Abdi İbrahim activities for the year 2020, calculated within the framework of the ISO 14604 standard, is shown on the left. Abdi İbrahim, which calculates all of its emissions from direct and indirect sources within scope 1, 2 and 3 limits, manages its environmental impacts from a broad perspective.

CARBON EMISSION		
Metric tons of CO ₂ equivalent	2019	2020
Scope 1 emissions*	7,067	16,436
Scope 2 emissions**	22,720	0
Scope 3 emissions***	9,621	5,808
Total carbon emissions (SC1+SC2)	29,787	22,244

* Covers the consumption of energy sources, such as electricity and natural gas, the amount of refrigerant gas used in cooling units, and energy consumption of building heating.


* There has been an expansion of coverage in the calculation. Data for 2019 is given for informational purposes only.

** Thanks to 100% renewable energy use, the carbon footprint is 0.

*** In 2020, the system limits and methodology of the corporate carbon footprint calculation were revised. 2020 is taken as the base year for values. Data for 2019 is given for informational purposes only.

Scope 1, Scope 2, and Scope 3 carbon emission values for 2019 and 2020 have been verified by the independent limited assurance study of PwC.

[p.90](#) You can find Abdi İbrahim's environmental performance indicators here.



Abdi İbrahim's environmental strategy has been established around the Organizational Life Cycle Assessment (O-LCA), and the company's efforts to decrease carbon emissions at each step of the value chain continue.

* This evaluation is organization based.

MEDICAL

A sense of responsibility that goes beyond legislation

Considering legal and ethical values in all business procedures, from clinical research to product safety, from licensing to market access and promotion, Abdi Ibrahim is highly sensitive about product and service quality.



Key Performance Indicators (KPI)

| GRI | 416-1 | 416-2 |

	<p>To address patient and healthcare personnel feedback quickly and comprehensively, during the use of the products</p>	<p>Questions on adverse reactions and medical information answered through e-mail or product information line →</p>	<p>1,029 2019</p>	<p>992 2020</p>
	<p>To ensure total compliance with legal regulations on product responsibility</p>	<p>Incidents constituting violations of Pharmaceutical Industry Marketing Legislation →</p>	<p>0</p>	
	<p>To create an internationally recognized pharmacovigilance system</p>	<p>Number of audits carried out by the Ministry of Health and licensing companies →</p>	<p>2019 1 Ministry of Health audit, 1 company audit</p>	<p>2020 2 company audits All audits successfully passed.</p>
	<p>Product development through industry-academy cooperation</p>	<p>CE Certificate and approval received in 2020 for a wound dressing developed with the cooperation of Abdi İbrahim and the Ege University Faculty of Pharmacy.</p>		
	<p>To carry out community health studies</p>	<p>The project which Abdi İbrahim has been carrying out separately and in parallel with other patient blood management studies it has been conducting for a long period in cooperation with business partner Vifor, was designed by the Ministry of Health with European Union funds and the work has already begun. Abdi İbrahim, which will support the physicians involved in the project, will contribute to the successful implementation of patient blood management throughout the country.</p>		

Medical

The Medical Affairs Directorship, which reflects Abdi İbrahim's compliance with ethical rules, is engaged in strategic partnerships in a wide range of businesses within and outside the company on the basis of compliance with ethical values and rules.

| GRI | 416-1 |

Business development and new products

The Medical Affairs Directorship, which plays an active role in new product development processes in line with Abdi İbrahim's future goals, contributes to the timely evaluation in the Business Development Department of the company's corporate strategies, in line with growth plans and ideas from the world of science and emerging therapeutic trends. Having evaluated 224 new molecules over the course of 2020, the Medical Affairs Directorship remained a contributor to the evaluation of products suitable for Abdi İbrahim's future goals, from an investment standpoint.

In this respect, Abdi İbrahim's aim is to offer the unique wound dressing formulation it has developed, in collaboration with the Ege University Faculty of Pharmacy, and for which it has registered the patent in many countries and received the CE Certificate and approval, for the use of patients by 2021.



Prof. Dr. Özgen Özer
Ege University Faculty
of Pharmacy, Head of
Pharmaceutical Technology
Department

For the commercialization of our wound care solution, invented by Dermis Pharma A.Ş. in the Ege Teknopark, the underlying academy-industry collaboration model has been established, with development studies conducted together with Abdi İbrahim. Thanks to this cooperation, the pioneering entrepreneurship steps being taken for the first time in our country to develop a bioactive wound dressing within a university, are under the same banner as a notable industry organization, and clinical studies were also conducted in this respect for the first time. A domestic product that provides a solution with high added value to wound care problems, which can compete with similar imported products in the medical device industry, will be launched in May 2021. The fact that this product is the first product to be developed in the medical field as a result of academy-industry cooperation, is evidence of Abdi İbrahim's commitment to its vision and mission. The exchange of ideas between Dermis Pharma and Abdi İbrahim gives rise to the development of other innovative models.

Thanks to the mutual trust created by this project, a series of cosmetic formulations and generic drugs have been developed in cooperation with Abdi İbrahim. In this context, eight newly graduated pharmacists were employed. As such, these post-graduate students have taken their first steps into professional life within a project. Abdi İbrahim's support for research will also increase the high-tech production capacity of the industry. When it comes to innovation in health, a triple spiral structure is indispensable in the cooperation of public, academy and industry, and this harmonious cooperation is a great example of this.



Training

The Medical Affairs Directorship is responsible for basic medical, pharmacovigilance, ethics and compliance, promotional activities and product trainings for newly recruited medical sales representatives and marketing staff. The Medical team, which has digitized all medical trainings for the first time in the Turkish pharmaceutical industry during the pandemic period, will also implement the digital education platform Ai Med Academy, the first application of digital transformation, in the first quarter of 2021. Every medical sales representative in Abdi İbrahim receives 60 trainings over the year. The global average training duration is 3-4 days, whereas this is 12-13 hours in Abdi İbrahim, reaching a total of 86 hours over the year.

Again, during the pandemic period, a bulletin called Viral Gündem (Viral Agenda) was prepared to ensure the delivery to more than 20 thousand physicians of the most up-to-date and accurate information about the pandemic and COVID-19, correct widespread misconceptions, and pass on up-to-date treatment approaches in many fields to less equipped physicians. In addition to all these innovations, the Medical Affairs Directorship participated in congresses and symposiums held for external stakeholders particularly in digital platforms, and supported all scientific and product promotion meetings held throughout the year by sharing information obtained from online advisory boards and publishing clinical study results. Moreover, it has contributed to the awareness of the society by sharing short, informative articles about the disease and general treatment principles during the awareness days concerning public health.

During the pandemic period, our medical team has digitized all medical training as an important first for the Turkish pharmaceutical industry, and as a result of the hard work of nearly 30 medical managers over nine months, the medical training for 140 products has become available on online platforms with interactive tools incorporating over 1,000 audio video recordings, hundreds of reminder screens and thousands of questions and answers.



Dr. Recep Erşahin
Abdi İbrahim Medical Director

- > **60** medical sales representative trainings in a year
- > Over **1,000** scientific and product promotion meetings
- > Over **1,000** videos and interactive tools for digital medical training relating to approximately **140** products

Promotion

With the pandemic, crisis management was established and the company's quick access to all the necessary information from a single source was ensured. This way, internal stakeholders were informed about the rapid implementation of the Turkish Medicine and Medical Devices Agency rules adapted to pandemic conditions throughout the year, giving direction to promotion and marketing activities while preventing their interruption.

The Medical Directorate continues to work without interruption on the re-preparation of all scientific material, by adapting their content and message to digital platforms,

their inspection according to SPC information and promotion directives, and for the delivery of up-to-date and objective information on the disease and treatment to healthcare professionals.

The Directorate, which sponsors more than 1,000 scientific and product promotion meetings, produces and contributes scientific content to the meetings. In addition to all these, within the Pharmaceutical Manufacturers Association of Turkey (İEİS), of which it is a member, it plays a leading role in the regulation amendments recommended by Turkish Medicines and Medical Devices Agency (TİTCK), as well as in determining the industry ethics and rules of the pharmaceutical industry.



Clinical Studies

Abdi İbrahim regularly carries out clinical research, aimed at finding new treatment methods and the improvement or comparison of existing treatment methods.

Increasing its budget allocation to clinical research every year, Abdi İbrahim carries out all its studies on this subject within the framework of the Good Clinical Practices (GCP) as well as the relevant legal legislation, especially the Clinical Trials Regulation published by the Ministry of Health. In addition to this, in line with the international legislation, Abdi İbrahim receives the approval of the Ethics Committee and the Authority, which is considered a prerequisite for global recognition, before commencing clinical research projects. In 2019 and 2020, it carried out retrospective and

observational studies in the field of clinical trials, which is divided into four stages, according to the nature of the research. The results of these studies have been presented at both national and international scientific platforms and also published as articles in medical journals. The Company continues with approval requests and design preparation for clinical trials planned for new pharmaceutical combinations, new indication receivals, and licensing in global markets, and it has given partial support to "Clinical Trials with Research Initiative" demands from doctors, provided that they are compliant with legislation.

| GRI | 416-1 |



Product Safety (Pharmacovigilance)

Abdi İbrahim regards product safety as one of its indispensable principles, and its pharmacovigilance system has been audited by the Ministry of Health and three foreign companies to be rated successful, in the year 2019 and 2020.

Abdi İbrahim, which records all kinds of safety information regarding the medicine in its product range and submits it to the relevant authorities, constantly evaluates the risks and benefits of the products for which it is responsible. The Company's Pharmacovigilance Department can be reached 24/7, and its product safety is based on the "Regulation on the Safety of Medicines" and guidelines published by the Ministry of Health. In its international activities, it makes great efforts to comply with pharmacovigilance laws and regulations in the relevant countries.

Abdi İbrahim considers it an ethical responsibility to monitor the undesirable effects of the drugs for which it is responsible, in accordance with the patient confidentiality principles and prepares periodic benefit/risk assessment reports and other safety reports analyzing the safety information relating to its products, to be submitted to the Ministry of Health. It also shapes in-house training activities within the framework of the principle of continuous improvement, and provides comprehensive training in the field of product safety to both its employees and the personnel of third party companies.

| GRI | 416-1 | 416-2 |

Authority and firm audits

In accordance with legal regulations, the Abdi İbrahim pharmacovigilance system is subject to the supervision of the Ministry of Health, and its activities are carried out within the framework of the relevant legislation, and according to the principles of "Good Pharmacovigilance Practices". The system, which is subject to regular internal audits in line with company procedures, was inspected by Ministry of Health agency TİTCK and three foreign companies in 2019 and 2020. These practices play a significant role in the improvement of the system.



Licensing and Market Access

Abdi İbrahim maintains its product licensing processes, one of the most important pillars of its business processes, within the framework of legal regulations and ethical values.

Abdi İbrahim conducts all its business processes within the framework of the legislation in force in Turkey, while closely following the regulations and guides published by international health institutions.

The Licensing Department is responsible for preparing the licensing files of medicinal products for human use containing chemical and biological active substances, managing the registration processes, as well as preparing the application file for products in the cosmetic, medical device and food supplement categories, obtaining approvals and supporting the procedures of placing the products on the market.

It is the responsibility of the Market Access Department to keep track of the reference prices of the existing products and make all necessary updates, to follow the price and reimbursement movements of the competing products and to give the necessary guidance, to determine the prices and discount rates that can be used in the selection of new projects.

It could be said that the licensing and market access department forms the bridge linking the pharmaceutical industry and the health authorities. As the employees of this department, we work to offer quality, effective and safe products to heal human health. We look at each product as a project and treat all of them with the same level of meticulousness.



Çiğdem Akyürek
Abdi İbrahim
Regulatory Affairs and
Market Access Director

In 2019 and 2020;

- › 44 trademark registration applications were made in eight countries.
- › 83 trademark registration applications were made and 44 trademarks were registered.
- › A total of 61 human medical product licenses, 18 of which are transfer licenses, and approvals for 16 food supplements, 25 medical devices and nine cosmetic, were obtained in Turkey; whereas in global markets 201 licenses were obtained in 29 countries.
- › In Algeria, local production approval was obtained for nine products in 2019 and 14 products in 2020.
- › With the product "Hametol" the first cosmetic product approvals in Kazakhstan and Bosnia-Herzegovina were obtained.
- › In various European countries, licenses were obtained for the tablets containing Posaconazole and Levothyron developed by Abdi İbrahim, and they have been prepared for launch.
- › As part of the strategically important localization project in Turkey, product manufacturing approvals of eight imported products were obtained.
- › Under the GMP (Good Manufacturing Practices) inspection requirement imposed by the Ministry of Health in 2009 for import license applications, inspections were carried out by the Ministry of Health for three production facilities abroad. GMP renewal applications were made for 13 facilities and 15 products.

In 2020;

- › Price increases were made for **49** products.
- › **34** products entered reimbursement.
- › Distribution certificates were obtained for **19** products and SSI procedures were completed.
- › **39** products have been added to the e-prescription list.
- › **10** products with their licenses transferred have been added to the SSI list.

Product Information and Consultation Line

Abdi İbrahim values developing relations with its stakeholders based on communication and transparency, providing services 24 hours a day, seven days a week, with its pharmacovigilance and medical evaluation line.

Abdi İbrahim provides product adverse event information through the pharmacovigilance and medical evaluation line it established at the end of 2019, and informs patients/patient relatives and healthcare personnel about quality complaints and reimbursement.

A total of 982 call were logged on this line over the course of 2020. For quality complaints, the Quality Assurance Directorate; for Medical Information, the Medical Affairs Directorate; and for adverse event notifications, the Pharmacovigilance Directorate reviewed and answered the records. In 2021, the Pricing and Market Access Directorate will also be integrated into the system for reimbursement.

Through this system, stakeholders are able to reach Abdi İbrahim 24 hours a day, 7 days a week, via telephone, fax and e-mail.

“From the Past to the Future: The Journey of Healing” Illustrations

5. As we further developed our Sustainability Report in terms of content, we have also moved it to the next level visually. We have combined our report with the design vision of collage artist Selman Hoşgör and included the illustrations designed by Hoşgör on our report cover and separator pages.

Hoşgör states that his aim is to design posters with peaceful, positive and healing energy that reflect the spirit of Abdi İbrahim, and his illustrations, based around 10 different themes, reveal Abdi İbrahim's "Healing Journey from the Past to the Future."

"Abdi İbrahim's passion for healing the future with the power it draws from its past, its efforts to discover new molecules, breakthroughs in biotechnology, the value it places on innovation and the environment, its goal to become a strong international brand, women's importance in the management and their key role regarding Abdi İbrahim's place today, the structure of the company intertwined with art" are manifested in these unique designs.

We also offer a pleasant dynamism in the sustainability section of our website, where these illustrations can be found animated.

www.abdiibrahim.com.tr/en/sustainability ➔

Through the Eyes of Selman Hoşgör...

Our cooperation with Abdi İbrahim has pleased me in many different ways. First of all, we have all become more aware of the healing powers of science and its importance, especially given the conditions we are facing today. I attach great value to the fact that Abdi İbrahim, as the leading company of the sector, focused on this value and make it a sustainable goal under various sub-headings. The established history of the company was another important motivation. Please note that I have specifically used the word "established" here. Because if you cannot connect your past values with the needs of the present, you will become obsolete. But what I saw before me was a well-established company that focuses on innovation and strives to adapt its values to its way of doing business. Finally, it was a very valuable experience for me to feel the desire for innovation, even though this is not a sector that comes first to mind when it comes to art. Thank you again for this collaboration.

Who is Selman Hoşgör?

Selman Hoşgör, who studied illustration and typography at Central Saint Martins after studying graphic design at Istanbul Kadir Has University, is a multidisciplinary visual artist working in London. Hoşgör produces collages combining photographs, typography and vibrant colors and has designed collages for Apple, Microsoft, Pirelli, Bulgari, Longines Masters, The Hollywood Reporter, Vanity Fair, Vogue Turkey, The Guardian, The Economist and Elle USA. Hoşgör discovered that he expresses himself best through collages. He likes utilizing his own creative world, and vivid colors appear to him "in the moment" exclusively during the creative process, to give him inspiration.



ANNEX 1 Company Policies

Quality Policy

Abdi İbrahim; complies fully with local and international quality standards, cGMP requirements and all relevant legal obligations in pharmaceutical production and all other applications, and with the quality of its products always provides a reliable service to human health. It works with determination, responsibility and passion for customer-oriented services, continuously improving its quality system with risk-based approaches and training in order to make it sustainable, to ensure its adoption by employees.

Environmental Policy

In all its activities, Abdi İbrahim considers the protection of the environment, continuous improvement, effective use of natural resources, full compliance with the law and the prevention of pollution, reduction and separation of wastes generated during its activities at source, and recycling and disposal with the most appropriate methods, as the basis of its environmental policy. Abdi İbrahim has obtained all legal permissions, as well as the ISO 14001 Environmental Management System Certificate.

Human Resources Policy

Abdi İbrahim regards each of its employees as a talent, and designs processes to reveal their potential so as to create the opportunity and environment for them to continuously develop. The priorities of the Company's human resources strategy, which adopts the principles of reliability and transparency, are as follows:

- › To provide an environment and atmosphere of passionate work,
- › To attain excellence in talent management and backup,
- › To establish a performance culture associated with strategic priorities,
- › To develop the technical competencies and leadership skills required by the strategy,
- › To create the system and sustainable procedures required by the HR infrastructure.

Occupational Health and Safety Policy

At all its facilities, Abdi İbrahim considers compliance with legal, international regulations and customer requirements, consistent development and the creation of a safe working environment with the participation of employee representatives, as the basis of its Occupational Health and Safety Policy. In addition to having all legal permits, Abdi İbrahim holds the ISO45001 Occupational Health and Safety Management System Certificate.

Information Security Policy

Abdi İbrahim is aware that one of the most important conditions for its reputation and the continuation of its services in the sector, is the timely, proper, appropriate and most effective protection of information. The main responsibilities of the company regarding the protection of information assets are:

- › Identifying the information assets of the institution,
- › Protecting the information of employees and all stakeholders,
- › Ensuring the confidentiality, integrity and accessibility of information assets,
- › Using information assets only for the purposes determined by the management,
- › Implementing the security policies and rules determined by the institution,
- › Keeping information security standards and processes up-to-date,
- › Keeping the information security awareness of the employees up-to-date by organizing trainings,
- › Reviewing the internal and external risks related to information security at certain intervals and to take the necessary precautions by conducting risk analyses.

Audits

2019 audits

- › Ukraine Health Authority
- › Russia Health Authority
- › Pakistan Health Authority
- › Peru Health Authority
- › Infarmed, Portugal Health Authority (EU GMP Certification Renewal)
- › Russia Health Authority
- › Turkish MoH (Ophthalmology)
- › Turkish MoH
- › Mylan
- › Zentiva
- › MSD
- › Helm
- › ISO 13485, PCBC (Polish Center)
- › Teva
- › Tchaikapharma
- › ISO 9001
- › Orifarm
- › Sanofi

2020 audits

- › Russia Health Authority
- › Turkish MoH (Clinical Research)
- › İE Menarini
- › Astra Zeneca
- › Sifi
- › Cristers
- › Glenmark
- › Teofarma
- › Fresenius
- › Intertek (on behalf of Biogaran)
- › ISO 9001

APPENDIX 2
Social Performance
Indicators

Data covers Abdi İbrahim's
operations in Turkey.

| GRI | 102-8 | 401-1 | 401-3 | 405-1 |

NUMBER OF EMPLOYEES				
	2017	2018	2019	2020
Turkey	3,402	3,394	4,042	3,918
Abroad	481	553	518	534
Total	3,883	3,947	4,560	4,452

EDUCATION STATUS		
	2019	2020
Master's degree and above	340	350
Bachelor’s degree and graduate school	2,837	2,695
Elementary and high school	865	873

AGE GROUP		
	2019	2020
30 years and younger	1,420	1,154
30-50 years	2,506	2,624
50 years and older	116	140

GENDER		
	2019	2020
Female	1,244	1,193
Male	2,798	2,725
Abdi İbrahim Tower (Headquarters)		
Female	242	192
Male	187	156
R&D Center		
Female	91	79
Male	50	48
Field		
Female	638	578
Male	1,777	1,644
Technical Headquarters (Factory)		
Female	364	358
Male	834	863
Countries		
Female	240	257
Male	278	277

GENDER DISTRIBUTION WITHIN TOP MANAGEMENT																
	Factory				Headquarters				Field				Grand total			
	2019		2020		2019		2020		2019		2020		2019		2020	
Title	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
Deputy Director and above	3	1	4	3	24	9	26	10	-	-	-	-	27	10	30	13
Manager	9	11	8	6	39	20	40	25	-	-	-	-	48	31	48	31
Executive	27	32	35	37	43	92	50	101	7	-	7	-	77	124	85	138
Total	39	44	47	46	106	121	116	136	7	-	7	-	152	165	163	182

MARITAL STATUS		
	2019	2020
Single	1,478	1,306
Married	2,564	2,612

BREAKDOWN BY WORKING AREAS		
	2019	2020
White collar	3,258	3,115
Blue collar	784	803

EMPLOYEE BREAKDOWN		
	2019	2020
Headquarters	443	475
Marketing	2,287	2,110
Medical Sales Representative	2,201	2,017
Regional Director	195	205
Factory	1,203	1,221
R&D	141	127

PERFORMANCE MANAGEMENT		
	2019	2020
Employees included in the performance system (Overseas incl.)	4,560	4,452
* The performance and career development of all employees are regularly monitored.		

MATERNITY LEAVE		
	2019	2020
Going on maternity leave	47	54
Returning from maternity leave	53	50

APPENDIX 3
Environmental
Performance
Indicators

Data relating to Abdi İbrahim's
Esenyurt Production Complex
in Turkey.

| GRI |
| 301-1 | 302-1 | 302-3 |
| 302-4 | 306-1 | 306-2 |

ENVIRONMENTAL PROTECTION INVESTMENTS			
Improvement investments			
Investment cost (TRY)	2018	2019	2020
Collection, transportation and disposal of waste	384,632	381,137	329,401
Waste water analyses	13,100	38,730	39,150
Domestic and industrial wastewater treatment plant	61,350	602,965	73,375
Activities related to permits such as environmental discharge, emission permit etc.	6,600	-	-
Emission measurements		76,503	33,920
In 2020, TRY 234,000 of environmental cleaning tax was paid.			
Preventive measures and environmental management investments			
ISO 14001 Environmental Management System and ISO 45001 Occupational Health and Safety Certificates audits	24,700	19,540	57,675

PRODUCTION AND HAZARDOUS WASTE QUANTITIES			
	2018	2019	2020
Actual production quantity (unit)	250,362,571	305,160,336	283,195,104
Actual hazardous waste amount (gr)	328,306,000	401,550,000	567,208,000
Target (gr)	362,090,000	362,700,000	454,200,000

PACKAGING MATERIALS AND RAW MATERIALS USED IN PRODUCTION			
(tons)	2018	2019	2020
Package	2,223	2,302	1,842
Box	484	755	487
Package insert	498	723	610
Plastics	296	414	900
Glass	7,862	9,140	2,436
Aluminum	375	546	320
Imported packaging	1,940	413	2,866
Domestic market raw materials	2,143	1,673	932
Imported raw materials	3,870	6,364	4,680
Total packaging material	13,678	14,144	9,461
Total raw material	6,013	8,037	5,612

AMOUNT OF HAZARDOUS WASTE PER UNIT			
(gr/unit)	2018	2019	2020
Result	1.3	1.3	2.0
Target	1.5	1.2	1.6

RECYCLABLE WASTE AMOUNTS			
(gr)	2018	2019	2020
Result	735,670,000	965,881,000	956,144,000
Target	764,390,000	983,390,000	1,111,550,000

PER UNIT RECYCLABLE WASTE AMOUNTS			
(gr/unit)	2018	2019	2020
Result	2.9	3.2	3.4
Target	3.1	3.2	3.9

RECOVERY AMOUNTS FROM PRODUCTS PUT ON THE MARKET			
(kg)	2018	2019	2020
Paper, cardboard	1,332,642	1,629,602	1,484,144
Plastics	27,083	33,040	33,302

AMOUNT OF WASTE RECYCLED IN THE FACTORY			
Waste type (kg)	Disposal method	2018	2019
Paper, cardboard	Recovery	393,940	405,920
Plastics	Recovery	123,390	140,340
Blister pack	Recovery	131,390	170,860
Glass	Recovery	24,320	21,630
Metal	Recovery	62,630	96,700
Drum, barrel, jerrycan	Recovery	107,756	124,771
Other (cartridge, accumulator, battery, electronics, cable, etc.)	Recovery	3,813	2,800
Contaminated packaging material	Disposal (incineration)	269,468	292,640
Dust and fluidized waste	Disposal (incineration)	27,633	35,143
Contaminated filter waste	Disposal (incineration)	7,064	15,273
Liquid laboratory waste	Disposal (incineration)	38,964	43,769
Fluorescent lamp	Disposal	219	236
Treatment sludge	Recovery	0	0
Domestic waste	Storage	336,102	420,275

DIRECT ENERGY CONSUMPTION BY ENERGY SOURCE			
	2018	2019	2020
Natural resource consumption			
Natural gas (m³)	2,628,183	3,418,905	4,361,727
Diesel (lt)*	30,150	22,830	44,182
Water (m³)	194,668	213,596	218,058
Electricity (kwh)	36,464,889	41,568,131	44,209,605
Natural resource consumption per unit			
Natural gas (m³)	0.010	0.011	0.015
Diesel (lt)	0.00003	0.0001	0.0002
Water (m³)	0.0006	0.0007	0.0008
Electricity (kwh)	0.0930	0.1362	0.1561
*Although diesel is consumed by the generators during power outages, 2,440 liters in 2019 and 2,690 liters in 2020 were used for outdoor forklifts.			
Compared to 2019, natural gas consumption increased by 27 percent, electricity consumption increased by six percent, diesel oil consumption increased by 83 percent, due to the higher rate of power outages than 2019, and water consumption increased by 0.3 percent in 2020.			

ENERGY/PRODUCTION AND SUPPLY RATIO

(%)	Renewable	Other
2018	10	90
2019	14.7*	85.3
2020	100	0
*Rate of renewable energy excluding hydropower plants according to TEİAŞ 2019 report.		

WASTE WATER ANALYSES

(mg/l)	2018	2019	2020
BOD5 output	40	30	17
COD output	272	150	167
Facility performance is monitored on a daily basis by the laboratory established within the waste water treatment facility. Some parameter values analyzed at the facility entrance and exit.			

WATER CONSUMPTION AMOUNTS

(m³)	2018	2019	2020
Well 1	59,438	56,644	50,271
Well 3	15,099	9,368	17,431
Well 4	40,129	35,275	40,325
Well 5	24,715	16,983	17,782
Well 6	10,237	13,645	363
İSKİ line	45,050	81,681	91,887
Total	194,668	213,596	218,058

AMOUNT OF WASTEWATER DISCHARGED



(m³)	2018	2019	2020
Wastewater discharge	128,007	142,446	100,620



Contributions to Sustainable Development Goals

| GRI | 103-2 | 201-1 | 203-1 | 203-2 | 416-1 | 416-2 |

Sustainable Development Goal	Targets Focused On	Contribution of Abdi İbrahim
 3 Good Health and Well-being	3.4 By 2030, reduce premature mortality from noncommunicable diseases through prevention and treatment; promote mental health and well-being	▸ Abdi İbrahim Foundation increases health awareness and provides aid to patients in need.
	3.6 By 2020, halve the number of global deaths and injuries from road traffic accidents	▸ Internally, the fatalities due to traffic accidents is 0% at Abdi İbrahim.
	3.8 Achieve universal health coverage, including financial risk protection, access to quality essential health-care services to safe, effective, quality and affordable essential medicines and vaccines for all	▸ The introduction of first biosimilar / generics for the original prescription medicines have multiple positive impacts on the public health budget. Abdi İbrahim's 3 generics medicines have resulted in an estimated total saving of \$45 million in the public health budget since 2019.
 4 Quality Education	4.4 By 2030, increase the number of people who have relevant skills for employment, decent jobs and entrepreneurship	▸ Abdi İbrahim has introduced new engineering programmes in technical high schools.
	4.b By 2020, expand the number of scholarships available to developing countries	▸ Abdi İbrahim offers scholarships for young scientists working on advance fields.
 5 Gender Equality	5.5 Ensure women's full and effective participation and equal opportunities for leadership at all levels of decision-making in political, economic and public life	▸ Women employees represent 31% of direct employment and the proportion of women in the managerial team is 37% in Turkey.

Sustainable Development Goal		Targets Focused On		Contribution of Abdi İbrahim
	8 Decent Work and Economic Growth	8.1	Sustain per capita economic growth in accordance with national circumstances	<ul style="list-style-type: none"> ▸ GVA generated as a result of Abdi İbrahim's economic activity totals to \$645 million.
		8.2	Achieve higher levels of economic productivity through diversification, technological upgrading and innovation	<ul style="list-style-type: none"> ▸ Abdi İbrahim generates significant indirect economic impact in the context of external benchmarks and stakeholder priorities. ▸ The GVA impact due to supply chain effects and increased spending of the employees are \$356 million.
		8.3	Promote development-oriented policies that support productive activities, decent job creation, entrepreneurship, creativity and innovation, and encourage the formalization and growth of SMEs	<ul style="list-style-type: none"> ▸ Having worked with approximately 1,233 suppliers in 2019 and 2020, the ratio of Abdi İbrahim's local suppliers to all suppliers is 68%.
		8.5	By 2030, achieve full and productive employment and decent work and equal pay for work of equal value	<ul style="list-style-type: none"> ▸ Abdi İbrahim directly contributes an average of \$73K of GVA for each employee in 2020
		8.6	By 2020, substantially reduce the proportion of youth not in employment, education or training	<ul style="list-style-type: none"> ▸ Abdi İbrahim directly employs 3,918 qualified personnel in Turkey. ▸ Apart from that, 15K number of jobs were created indirectly and through induced effects.
		8.8	Protect labor rights and promote safe and secure working environments for all workers, including migrant workers	<ul style="list-style-type: none"> ▸ The fatal and non-fatal occupational injuries are 3.52% for the facility and 0.25% for the HQ in 2020.
	9 Industry, Innovation and Infrastructure	9.2	Promote inclusive and sustainable industrialization and, by 2030, raise industry's share of employment and GDP, in line with national circumstances	<ul style="list-style-type: none"> ▸ \$68 million revenue is generated through Abdi İbrahim manufacturing services. ▸ The manufacturing and quality employment's share is 24% within total employment.
		9.4	By 2030, upgrade infrastructure and retrofit industries to make them sustainable, with increased resource-use efficiency and greater adoption of clean and technologies and industrial processes	<ul style="list-style-type: none"> ▸ The actual carbon emission resulting from the use of natural gas at Abdi İbrahim Production Facilities is calculated as 8,855 metric tons / year for 2020.
		9.5	Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, including, by 2030, encourage innovation and increase the number of R&D workers and spending	<ul style="list-style-type: none"> ▸ Abdi İbrahim spent \$9 million on R&D in 2020 and became the undisputed leader in funding for scientific research and development with investment growing at a level of 14.6% from 2016 to 2020.

Sustainable Development Goal		Targets Focused On		Contribution of Abdi İbrahim
	10 Reducing Inequality	10.3	Ensure equal opportunity and reduce inequalities of outcome, including by eliminating discriminatory laws, policies and practices	<ul style="list-style-type: none"> At Abdi İbrahim the ratio of the basic salary and remuneration of women to men for each employee category is 1/1.
		10.b	Encourage official development assistance and financial flows, including foreign direct investment, to States where the need is greatest	<ul style="list-style-type: none"> Abdi İbrahim generated \$70 million FDI.
	12 Responsible Consumption and Production	12.2	By 2030, achieve the sustainable management and efficient use of natural resources	<ul style="list-style-type: none"> Abdi İbrahim has subjected the life cycle of YouPlus Multi Ener G food supplement to an environmental impact analysis in accordance with the ISO 14040/44 Life Cycle Assessment standard. With this analysis, the water use potential, resource use, fossil, mineral and metal contents of the product were evaluated alongside the impact on global warming, ozone layer depletion, ozone-induced photochemical smoke formation and acidification. The global warming potential of the product was determined as 0.224 Co2 eq and the water use potential as 0.293 m³ of deprivation.
		12.4	By 2020, achieve the environmentally sound management of chemicals and all wastes throughout their life cycle, reduce their release to air, water and soil in order to minimize their adverse impacts on human health and the environment	<ul style="list-style-type: none"> In 2020 the recycling reached 3.4%. Recovery amounts of paper from products on the market rose to 1,484,111 metric tons and plastic to 32,847 metric tons in 2020. In terms of wastewater, the BOD5 value calculated was 17 mg/L and the COD value 167 mg/L in 2020.
		12.5	By 2030, substantially reduce waste generation through prevention, reduction, recycling and reuse	<ul style="list-style-type: none"> Recyclable Waste at the Facility 954K (kg) Domestic Waste 339K (kg) Hazardous Waste Amount 417K (kg) Recovery Rate in Medicine Package (100%)
		12.6	Encourage companies to adopt sustainable practices and to integrate sustainability information into their reporting cycle	<ul style="list-style-type: none"> Abdi İbrahim shares a publicly accessible sustainability report prepared according to the GRI criteria every two years since 2013
		12.8	By 2030, ensure that people everywhere have the relevant information and awareness for sustainable development and lifestyles in harmony with nature	<ul style="list-style-type: none"> Abdi İbrahim provides information of all its products on product safety (pharmacovigilance). The firm also informs the public about procedures for product and service content, particularly with regard to substances that might produce an environmental or social impact via its sustainability reports.








Sustainable Development Goal		Targets Focused On		Contribution of Abdi İbrahim
	13 Climate Action	13.2	Integrate climate change measures into national policies, strategies and planning	<ul style="list-style-type: none"> Abdi İbrahim has pledged its support to SBTi. it is a commitment from Abdi İbrahim to how much it will reduce greenhouse gas emissions and sets targets. in this context, the contribution is made to the 2 °C reduction target in climate change. The actual carbon emission resulting from the use of natural gas at Abdi İbrahim Production Facilities is calculated as 6,676 metric tons/year for 2019 and 8,855 metric tons/year for 2020. Abdi İbrahim's efforts will intensify over the years with the objective to become carbon neutral by 2030, and the goal of leading the low carbon transformation of the Turkish pharmaceutical industry.
		17	Partnerships for the Goals	<ul style="list-style-type: none"> Tax contribution exports and foreign direct investment (FDI) are computed and included under the GVA impact of Abdi İbrahim. Abdi İbrahim's direct contribution to government budget from its economic activities totals to \$25 million.
	17 Partnerships for the Goals	17.1	Strengthen domestic resource mobilization, including through international support to developing countries, to improve domestic capacity for tax and other revenue collection	<ul style="list-style-type: none"> Abdi İbrahim generated \$70 million FDI since 2017.
		17.3	Mobilize additional financial resources for developing countries from multiple sources	
		17.11	Significantly increase the exports of developing countries, in particular with a view to doubling the least developed countries' share of global exports by 2020	<ul style="list-style-type: none"> Abdi İbrahim is solely responsible for 5% of the total exports of the \$1.3 billion pharmaceutical industry in Turkey with a \$70 million export volume in 2020.

GRI Content Index






For the SDG Mapping Service, GRI Services has reviewed the pairing of descriptions found in content index with SDGs for correctness. This service is available in the Turkish version of the report.









GRI Standard		Page Number/Direct Source	UNGC Principles (United Nations Global Compact)	Related SDG (Sustainable Development Goals)
GRI 101: Fundamentals 2016				
GRI 102: General Disclosures 2016				
GRI 102: General Disclosures 2016	Corporate Profile			
	102-1	3		
	102-2	18-21		
	102-3	107		
	102-4	18-19		
	102-5	31		
	102-6	53-54		
	102-7	18-21, 44		
	102-8	88-89	6	8
	102-9	55		
	102-10	18-21, 55		
	102-11	35, www.abdiibrahim.com.tr/en/corporate/our-business-ethics-principles	7	
	102-12	37		
	102-13	37	1, 8	



















GRI Standard	Page Number/Direct Source		UNGC Principles	Related SDGs
GRI 102: General Disclosures 2016	Strategy			
	102-14	4-5		
	102-15	8-16, 35		
	Ethics and Integrity			
	102-16	22, 35, 87	1, 4, 5, 6, 7, 8, 10	16 
	102-17	35	10	16 
	Governance			
	102-18	31		
	102-19	9, 31		
	102-20	9		
	102-21	12-14		16 
	102-22	31, 34		5  16 
	102-23	31		16 
	Stakeholder Engagement			
	102-40	36		
	102-41	59		8 
	102-42	12		
	102-43	12		
	102-44	12		








GRI Standard		Page Number/Direct Source	UNGC Principles	Related SDGs
GRI 102: General Disclosures 2016	Report Profile			
	102-45	3		
	102-46	3, 11		
	102-47	11		
	102-48	Not available.		
	102-49	Not available.		
	102-50	2019-2020		
	102-51	2018-2019		
	102-52	2 years		
	102-53	3, 107		
	102-54	3		
	102-55	97-106		
	102-56	Not available.		
GRI 200: Economic Standard Series				
	Economic Performance			
GRI 103: Management Approach 2016	103-1	12-16, 29-33, 43-44, 94-96	7, 8, 9	
	103-2	12-16, 29-33, 43-44, 94-96		
	103-3	12-16, 29-33, 43-44, 94-96		
GRI 201: Economic Performance 2016	201-1	43-44, 94-96		<div>8</div> <div>9</div>

















GRI Standard		Page Number/Direct Source	UNGC Principles	Related SDGs
	Indirect Economic Impacts			
GRI 103: Management Approach 2016	103-1	12-16, 29-33, 43-44, 93-96	7, 8, 9	
	103-2	12-16, 29-33, 43-44, 93-96		
	103-3	12-16, 29-33, 43-44, 93-96		
GRI 203: Indirect Economic Impacts 2016	203-1	42-51, 93-96		
	203-2	42-51, 93-96		  
	Procurement Practices			
GRI 103: Management Approach 2016	103-1	12-16		
	103-2	8-16, 31-36		
	103-3	8-16, 31-36		
GRI 204: Procurement Practices 2016	204-1	55		
	Anti-Corruption			
GRI 103: Management Approach 2016	103-1	12-16, 35		
	103-2	12-16, 35		
	103-3	12-16, 35		
GRI 205: Anti-Corruption 2016	205-1	12-16, 35	10	






GRI Standard		Page Number/Direct Source	UNGC Principles	Related SDGs
GRI 300: Environmental Standard Series				
	Materials			
GRI 103: Management Approach 2016	103-1	71-74, 87		
	103-2	71-74, 87		
	103-3	71-79		
GRI 301: Materials 2016	301-1	90	8	12 ∞
	Energy			
GRI 103: Management Approach 2016	103-1	71-74, 87		
	103-2	71-74, 87		
	103-3	71-79		
GRI 302: Energy 2016	302-1	77, 91-92	7, 8, 9	7 ☀️ 8 📈 12 ∞ 13 👁️
	302-3	75-77, 91-92	7, 8, 9	7 ☀️ 8 📈 12 ∞ 13 👁️
	302-4	75-77, 91-92	7, 8, 9	7 ☀️ 8 📈 12 ∞ 13 👁️
	302-5	75-79	7, 8, 9	7 ☀️ 8 📈 12 ∞ 13 👁️

GRI Standard		Page Number/Direct Source	UNGC Principles	Related SDGs
	Water			
GRI 103: Management Approach 2016	103-1	71-79, 87		
	103-2	71-79, 87		
	103-3	71-79		
GRI 303: Water and Wastewater 2018	303-1	92	7, 8, 9	
	303-3	Water is not recovered, as it may pose a risk in terms of quality.		
	303-5	92		
	Biodiversity			
GRI 103: Management Approach 2016	103-1	71-79, 87		
	103-2	71-79, 87		
	103-3	71-79		
GRI 304: Biodiversity 2016	304-1	Abdi Ibrahim does not have operations in high biodiversity areas.	7, 8, 9	6  14  15 
	304-4	Abdi Ibrahim has no activities in the habitats included in the IUCN Red List.	7, 8, 9	6  14  15 

GRI Standard		Page Number/Direct Source	UNGC Principles	Related SDGs
	Emissions			
GRI 103: Management Approach 2016	103-1	71-79, 87		
	103-2	71-79, 87		
	103-3	71-79		
GRI 305: Emissions 2016	305-1	78-79	7, 8	    
	305-2	78-79	7, 8	    
	305-5	78-79	7, 8	  
	Wastewater and Waste			
GRI 103: Management Approach 2016	103-1	71-79, 87		
	103-2	71-79, 87		
	103-3	71-79		
GRI 306: Wastewater and Waste 2016	306-1	75, 77, 92	7, 8, 9	
	306-2	90-92	7, 8, 9	 
	306-5	The wastewater generated in the Abdi İbrahim Esenyurt Production Complex is treated with MBR technology to obtain water quality that is well under discharge thresholds and is subsequently discharged into the municipality sewage system. The wastewater is treated again in this sewage system, which is connected to the municipal wastewater treatment system. As such, the wastewater is brought to a very high level of quality well below discharge thresholds, and does not harm the biodiversity of the receiving medium.	7, 8, 9	 

GRI Standard		Page Number/Direct Source	UNGC Principles	Related SDGs
	Environmental Compliance			
GRI 103: Management Approach 2016	103-1	71-79, 87		
	103-2	71-79, 87		
	103-3	71-79		
GRI 307: Environmental Compliance 2016	307-1	During the reporting period, Abdi Ibrahim has not been subject to any fines, in cash or in kind, for non-compliance with environmental laws and regulations.	8	16 
GRI 400: Social Standard Series				
	Employment			
GRI 103: Management Approach 2016	103-1	56-61, 87		
	103-2	56-61, 87		
	103-3	56-61		
GRI 401: Employment 2016	401-1	88-89	6	5  8  10 
	401-3	89	6	5  8 
	Employee-Management Relations			
GRI 103: Management Approach 2016	103-1	61, 87		
	103-2	61, 87		
	103-3	61, 87		
GRI 402: Employee Management Relations 2016	402-1	Minimum notice periods due to operational changes are in full compliance with laws and regulations.	1	8 

GRI Standard		Page Number/Direct Source	UNGC Principles	Related SDGs
		Occupational Health and Safety		
GRI 103: Management Approach 2016	103-1	61, 87		
	103-2	61, 87		
	103-3	61, 87		
GRI 403: Occupational Health and Safety 2018	403-1	61, 87	1, 6	8 
	403-2	61, During the reporting period, there have been no work related accidents that have caused death or serious injury.	1, 6	8 
	403-3	Abdi Ibrahim does not have any work procedures that could expose its employees to high-risk diseases.	1, 6	8 
	403-4	61	1, 6	8 
	403-5	61	1, 6	8 
	403-6	61	1, 6	3 
	403-7	61	1, 6	3 
	403-9	61	1, 6	3  8 
		Education and Training		
GRI 103: Management Approach 2016	103-1	56-61, 87		
	103-2	56-61, 87		
	103-3	56-61		
GRI 404: Training and Education 2016	404-1	57	6	4  5  8 
	404-2	60	6	8 
	404-3	89	6	5  8  10 

GRI Standard		Page Number/Direct Source	UNGC Principles	Related SDGs
		Diversity and Equal Opportunity		
GRI 103: Management Approach 2016	103-1	56-61, 87		
	103-2	56-61, 87		
	103-3	56-61		
GRI 405: Diversity and Equal Opportunity 2016	405-1	31, 58, 88-89	6	5  8 
		Non-Discrimination		
GRI 103: Management Approach 2016	103-1	56-61, 87		
	103-2	56-61, 87		
	103-3	56-61		
GRI 406: Non-Discrimination 2016	406-1	95 There were no cases of discrimination in the reporting period.	6	5  8 
		Customer Health and Safety		
GRI 103: Management Approach 2016	103-1	12-16, 80-85		
	103-2	12-16, 80-85		
	103-3	12-16, 80-85		
GRI 416: Customer Health and Safety 2016	416-1	12-16, 80-85, 93		
	416-2	93-95 There were no cases of non-compliance with health and safety practices of the products and services during the reporting period.		16 

INFORMATION

Abdi İbrahim Contact

For more detailed information about the Abdi İbrahim Sustainability Report, as well as your comments and suggestions:



Dr. M. Oğuzcan Bülbül

Public Affairs and Corporate Communications Director
oguzcan.bulbul@abdiibrahim.com.tr ➔



Megi Erpardo

Public Affairs Manager
megi.erpardo@abdiibrahim.com.tr ➔



Buket Koral Gönüllü

Corporate Communications Manager
buket.koral@abdiibrahim.com.tr ➔



Esra Koca

Corporate Communications Supervisor
esra.erdinc@abdiibrahim.com.tr ➔

Abdi İbrahim Tower

Address: Reşitpaşa Mahallesi,
 Eski Büyükdere Caddesi No: 4
 Maslak-Sarıyer 34467 İstanbul, Turkey
 Phone: +9 0212 366 84 00
 Fax: +9 0212 276 20 20

Abdi İbrahim Esenyurt Production Complex

Address: Orhan Gazi Mahallesi,
 Tunç Caddesi No: 3
 Esenyurt 34555 İstanbul, Turkey
 Phone: +9 0212 622 66 00
 Fax: +9 0212 623 19 52

Content and Design

Editorial Tasarım Ltd. Şti.

editorial@editorial.com.tr
 +9 0212 939 38 26

E D İ
T O R
Y A L

LEGAL WARNING

The 5th Sustainability Report (Report) of Abdi İbrahim has been prepared in accordance with the Global Reporting Initiative (GRI) Reporting Principles and the United Nations Global Compact (UNGC), Women's Empowerment Principles (WEPs) and UNGC CEO Water Mandate Progress Communications. This report has been prepared with the sole purpose of informing Abdi İbrahim İlaç San. ve Tic. A.Ş. stakeholders, and the content and information contained within has been created based on resources and information that were considered accurate and reliable at the time of writing. The information and content contained in the Report cannot be interpreted as any declaration, warranty and/or commitment, and it is not guaranteed that the information and content are complete and unchangeable. All rights of the report belong to **Abdi İbrahim İlaç San. ve Tic. A.Ş.**



ABDİİBRAHİM

- ✉ info@abdiibrahim.com.tr
- 🌐 www.abdiibrahim.com.tr
- 🐦 twitter.com/abdiibrahimilac
- 📷 [instagram.com/abdiibrahimilac](https://www.instagram.com/abdiibrahimilac)
- 📘 [facebook.com/abdiibrahimilac](https://www.facebook.com/abdiibrahimilac)
- 📺 [youtube.com/abdiibrahimilac](https://www.youtube.com/abdiibrahimilac)
- 🌐 [linkedin.com/company/abdi-ibrahim-pharmaceuticals](https://www.linkedin.com/company/abdi-ibrahim-pharmaceuticals)